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Chapter 1 
GENERAL INTRODUCTION 
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It is generally accepted that cell mediated immunity (CMI) has more importance 
in the control of cancer than the antibody-mediated immune response. The cell 
mediated immune response is the basis of the so-called natural host resistance 
to cancer, which is also referred to as "immunosurveillance". Although the 
concept of immunosurveillance has been much debated over the past decades, 
there is now no doubt that suppression of the immune function increases the 
incidence of a few types of cancer. Also, spontaneous regression has been 
observed for some tumors, including melanoma, renal cell carcinoma, and 
lymphoma, and evidence for a role of immunosurveilance is well supported in 
these tumors [1-3]. 
The role of a cell mediated immunosurveilance in patients with a head and neck 
squamous cell carcinoma (HNSCC) is less clear. Immunosuppressed patients 
do not develop head and neck cancer more frequently and spontanous 
regression is at most anecdotal. Despite this, defects of the CMI in HNSCC 
patients have extensively been documented. One of the first tests to reflect the 
status of the CMI which was found abnormal in HNSCC patients, was delayed 
type hypersensitivity (dth) as measured by skin reactions to ONCB (2,4-
dinitrochlorobenzene). Ninetyfive percent of the normal adult popUlation react 
with a dth reaction towards skin-applied ONCB, however such a positive 
reaction is often absent in HNSCC patients [4J. These observations have not led 
to a present clinical use of ONCB skin testing, but over the past decades other, 
more specified defects of the CMI have become clear. These defects are 
predominantly caused, on one hand by outside factors, like smoking, alcohol 
and malnutrition, on the other hand are CMI defects caused by factors resulting 
from, or produced by the tumor itself. In an effort to restore the immune 
defects, and to neutralize at least some of these immunosuppressive factors, 
or simply to boost the immune system, various immunotherapies have been 
attempted in HNSCC patients. These efforts have at present not led to positive 
clinical results that justify the widespread use of these strategies. Furthermore, 
it is not at all clear if the incapacity of the immune system to deal with tumor 
growth is the direct result of these so-called "defects" in the function of its 
various components and cells, or that the cancers have yet other more 
important mechanisms to escape a presumed immunosurveillance. Given the 
more widespread application of CD markers to identify various leucocytes (table 
I); given the ongoing discovery of new cytokines and growth factors, their role 
in tumor growth (control) and their potential therapeutic qualities; given the 
rapid development of new laboratory techniques including tumor genetics, and 
the lack of progression in treatment outcomes of HNSCC patients over the past 
3 decades, head and neck cancer immunology will continue to be an important 
field of research. 
HNSCC tumor antigens, -T lymphocyte recruitment and T lymphocyte 
stimUlation 
Head and neck carcinomas are infiltrated by lymphocytes referred to as TILs 
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Table I. CD markers respectively for T cells, B cells, monocytes/macrophages, dendritic cells and 
NK cells 
CD Name 
T cells 
CD2 T11 antigen; LFA-2 
CD3 T3 antigen 
CD4 T4 antigen 
CDS TS antigen 
CDlla LFA·l antigen 
CD25 Tac antigen 
CD2S Tp44 antigen 
CD45 LCA; T200 antigen 
CD45RO Restricted LeA 
CD45RA restricted LeA 
B cells 
CD5 T1 antigen 
CD19 Pan-B cell antigen 
CD20 B cell antigen 
CD22 B cell antigen 
Smlg Surface membrane 
immunoglobulin 
Monocytes/macrophages 
CD11 b,c Adhesion molecule on 
CD14 
CD6S 
monocytes/macrophages 
Monocytic antigen 
Macrophage antigen 
Dendritic cells 
C01 T6 antigen 
CD83 HB15 molecule 
SIOO 
NK cells 
CD16 
CD56 
CD57 
CD 
eR 
ICAM 
IgG 
LeA 
FeyRlll 
NCAM 
Human natural killer 
cell antigen 
Cluster of differentiation 
Complement receptor 
Intercellular adhaeslon molecule 
Immunoglobulin G 
leukocyte common antigen 
Function 
Receptor for T cell activation; ligand for lFA·3 
Associated with TCR; signal transduction from TCR to 
cytoplasm 
Involved in MHC-class II restricted antigen recognition 
Involved in MHC-class I restricted antigen recognition 
Adhesion molecule binds to ICAM-l and ICAM-2 
IL-2 receptor/activation T cells (8 celfs and macro phages) 
Receptor for 87/88-1 antigen on activated B-cells/ T cells 
proliferation 
Function unknown, common leukocyte antigen 
Activated (memory) T cells 
Virgin T cells, monocytes 
Function in T cell proliferation, unknown function in 8 
cells 
Function in 8 cell activation 
Function in 8 cell activation 
Function in B cell adhesion and activation 
Binding molecule for antigens 
MAC-l antigen, p150-95 antigen; associated with 
COla antigen/adhesion molecule 
LPS receptor 
Function unknown 
MHC-like protein (antigen-presentation) 
Function unknown 
intracellular growth factor 
Low affinity Fe receptor for IgO (also present on 
macro phages) 
Function unknown 
Function unknown 
LFA 
LPS 
MHC 
NCAM 
TCR 
leukocyte function antigen 
Upopolysaccharide 
Major histocompatibility complex 
Neural adhaeslon molecule 
T cen receptor 
Adapted from: -rmmunofenotypering In de diagnostlek: IndicatiesteUingen, uitvoering en lnterpretatle (Eds. van Dongen JJM, 
Groeneveld K, Adriaansen HJ, Hooljkaas HI, Rotterdam, Erasmus Universiteit, 1994. 
(tumor infiltrating lymphocytes). This infiltrating lymphocyte population 
constists mainly of CD3 + CD4 + T cells (with mainly a helper function) and 
CDS + T cells (with mainly a cytotoxic function). 
tissues 
adhesion molecules 
Involved 
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chemokines 
tumor 
Fig. 1. A schematic representation of the attraction of blood leukocytes to a tumor area. Factors Including cytokines and 
chemoldoos released by the tumor affect the blood ffow and endothelium (expressIon of adhesion molecules) such 
that marginating leukocytes start to roll, become activated, adhere and transmigrate. Selectlnes and glycosylated 
groups are predomInantly involved In the early process of rolling, whereas Integrins and Intercellular adhesion 
molecules are predomInantly Involved In a later firm adhesIon and tral1SmJgration of the leukocytes. Chemokinas 
released by the tumor direct the migration of the leukocytes towards the cancer cells. 
The process of lymphocyte recruitment into a tumor includes different steps 
(fig. 1): (a) activation of the endothelium in the cancer area and (b) rolling of the 
lymphocytes along the vessel wall, followed by (c) activation of the 
lymphocytes resulting in a firm adhesion, and finally (d) extravasation of the 
cells (crawling along the endothelium, diapedesis, and migration into the 
carcinomatous tissue), presumably in response to a chemoattractant gradient 
[5]. In the tumorous area locally released factors may (a) activate the 
endothelium, (b) attract and/or (c) activate the leukocytes. Factors which can 
activate the endothelium are cytokines like IL-1 CJ., IFN-y and TNF-CJ., leukotrienes, 
trombin and histamin [6-8]. Activated endothelial cells express high levels of 
adhesion molecules such as P-selectin (GMP-140, PADGEM), E-selectin, ICAM-1 
and VCAM-1 [6,9-11], which make them more adhesive for the passing 
leukocytes. Furthermore, activation of the endothelium increases vascular 
permeability and vasodilatation [12]. Chemokines can be trapped on the luminal 
surface of the endothelial cells and therefore promote attraction and activation 
of the passing leukocytes [13]. Activation of the passing leucocytes upregulate 
their integrin expression leading to a much stronger adherence to the endothe-
lium. Hence, a network of activating and chemoattractive factors is emerging 
that will able marginating lymphocytes to adhere and transmigrate through the 
endothelial wall into the tissue. 
After migration into the tissues the infiltrating T cells must recognize antigens 
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for further activation. If and how T cells recognize autologous human cancers 
is not known, but the concept of immunosurveillance implies that T cells are 
capable of detecting antigens specific for malignant cells, the tumor-associated 
antigens (TAA). These TAA are in case of head and neck cancers related to 
various oncofetal antigens, the epidermal growth factor receptor, viral antigens, 
and a number of surface glycolipids and glycoproteins and other TAA (table II) 
Table II. Tumor-associated antigens and monoclonal antibodies raised against these antigens In 
head and neck malignancies 
Antigen Monoclonal antibody 
CEA 
OFA (phase-specific 44 and 200-kDa antigens) 
22-kD surface antigen 
Poorly differentiated basal cells (50-55 kDa) 
Highly differentiated supra basal cells 
A-431 tumor eel/line 
Cell lines 183A. 1483 
Nuclear protein 
Transferrin receptor 
17-1A, epithelial cell surface 
Basal membrane structure 
Cytokeratin-associated 
Membrane surface (48 kDa) 
CEA = carc!noembryonic anl1gen 
OFA = oncofetal antigen 
GCOFP = gross cystic disease fluid protein 
anti·CEA-MoAb (clone F023C5) 
MoAb 115 
E48 F(ab')2 
K984 
K928 
UCD/AB 6.01 
MoAb R1·EGFR 
Ki·67 
RPN·611 
K931 
UM-A9 
174H.64 
SQM1 
Adapted from M. Hopsu and K.J.A. Ka!rsmo, Acta Oocol. 32:735, 1993 
[14]. Oncofetal antigens include carcino embryonic antigen (CEA) and a 44- and 
200 kD oncofetal antigen recognized by a monoclonal antibody (moab) 115. 
Viral antigens are mainly related to the human papilloma virus (HPV) 16 E gene 
products, but are only present in a minority of the head and neck cancers [15]. 
Epstein-Barr Virus (EBV) related antigens do occur only in nasopharyngeal-
carcinomas [16], 
Aberrant glycosylation is a common feature of malignancy. Alteration in cell 
surface carbohydrates accompanies malignant transformation which results in 
the appearance of TAA influencing both tumor growth and spread. Changes in 
cell surface glycoconjugate expression may result from absence or activation 
of new tumor-related glycotransferases. It is therefore not surprising that cell-
lines from squamous cell carcinomas of the head and neck are characterized by 
the presence of receptors for various lectins (detecting glycosylated structures) 
such as for ConA, PNA, DBA and WGA [17]. 
A considerable number of yet other TAA that are relatively specific for HNSCC 
has also been discovered via monoclonal antibodies (moabs) that were 
developed with the aid of HNSCC cell-lines or tissue specimen. These include 
amongst others the moab E 48, recognizing a 22 kD surface antigen [198; the 
moab K931, recognizing the so-called 17-IA surface antigen [19]; the moab 
UM-A9, recognizing a basal membrane structure [20]; the moab 174H.64, 
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recognlzmg a cytokeratin-associated antigen [21], and the moab SaM 1, 
recognizing a 4B kD membrane surface antigen [22]. 
T cells will only recognize TAA when they are presented as short linear peptides 
bound to major histocompatibility complex (MHC) molecules on the surface of 
cells (fig. 2) (23]. In this sense, CD4 + T cells are MHC class II "restricted", 
while COB + T cells are MHC class I "restricted". MHC class I molecules are 
expressed by nearly all cells in the body; MHC class II is mainly expressed on 
special cells, the so-called professional antigen presenting cells (APCs), 
including dendritic cells, macrophages, B cells and some subsets of T cells. 
Dendritic cells (DC) are, however, the most efficient (professional) antigen-
presenting cells (APC) due to a variety of factors, amongst which are the earlier 
mentioned constitutive expression of MHC class II molecules, but also the 
expression of costimulatory and adhesion molecules, and other characteristics 
such as motility [24,25]. 
Tcell antigen presenting cell 
Fig. 2. A schematic representation of the various ligand-receptor Interactions between an antigen-presenting cell end a 
T cell necessary to elicit the effective triggering of tho T cell. Firstly there Is the antigeruc peptide (black dot) in 
the groove of the MHC-class I or II molecule that specifically triggers the T cell receptor (TeR) via the C03 
complex, also involving CD4 or COB signalling (In the case of MHC class II and I respectively). There are further 
activation sIgnals necessary for giving signal 1 In the T cell In the form of the triggering of the CD2 molecule (by 
C05S), the CD111CD18 complex (by CD54) and the CD40·tigand molecule (by C040). 
If only signal 1 is given the T cell becomes anergic. For an effective activation of the T cell signal 2 Is necessary. 
This signal Is given via a stimulation of the CD28 molecule (by CDSO or 87·1). PTK ~ phosphotyroslne kInase 2nd 
messenger systems. 
The genes encoding for both MHC class I and II molecules are members of the 
immunoglobulin supergene family. These genes in the human species are 
arranged on chromosome 6 [26]. MHC class I genes encode for the Human 
Leucocyte Antigens (HLA) A, B, and C. MHC class II genes encode the HLA DP, 
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DQ, and DR antigens. The encoded HLA molecules are dimers, and comprise an 
a and Jl chain. The a-chain of the MHC class I molecules is encoded in the MHC 
genes, the Jl-chain is termed beta-2-microglobulin and is encoded on a separate 
chromosome. 
The overall structures of the class I and" MHC molecules are comparable [27]. 
The molecular confirmation of the chains forms a groove in which the antigenic 
peptide is presented. Thus the ability of antigenic peptides to be associated 
with class I or class " MHC molecules is governed by the actual molecular 
confirmation (tertiary structure) of the antigen-binding groove. It is therefore not 
surprising that organisms with a particular genetic make-up of MHC class I and 
" molecules have a special capacity to generate immune responses towards 
specific microbial and 'self' antigens. 
An additional molecule, known as the invariant chain, is intimately involved in 
the biology of HLA class II molecules. The invariant chain is a membrane 
glycoprotein, encoded by a non-HLA gene on chromosome 5. The "invariant" 
designation stems from the observation that, in contrast to the extensive 
polymorphism of some class II a and all class II Jl chains, the invariant chain is 
nonpolymorphic. It forms a trimer with the class " a and Jl chains in the 
endoplasmic reticulum during biosynthesis of the MHC-class " molecules and 
directs the trafficking of the trimer through the posttranslational machinery of 
the cell to the endosomal compartment. Current evidence indicates that the 
invariant chain also prevents peptides from binding in the class" groove until 
the class " molecule is delivered to the endosome. The invariant chain then 
dissociates from the class" molecule, which can consequently bind antigenic 
peptides processed from exogenous antigens taken up by the APC and 
degraded in its lysosomal compartment. The latter fuses with endosomes 
[2B-30]. The complex of the class II molecule with its bound peptide is then 
transported to the cell membrane; however, the mechanism of transport is still 
unclear. Due to this intracellular pathway, exogenous antigens are mainly 
presented in association with MHC class" molecules [31]. Peptides associated 
with MHC class" molecules can only be presented to CD4 + T cells [32], since 
the CD4 molecule is a special receptor for the MHC class" molecules. 
Endogenous antigens, e.g. viral antigens, are degraded by the low molecular 
mass polypeptide complex present in the cytoplasm [33]. Peptides are then 
delivered to the MHC class I molecules in the lumen of the endoplasmatic 
reticulum. After incorporation of the antigenic peptides into the groove and 
exposure of the MHC class I molecules on the cell surface, only COB + T cells 
are able to recognize such peptides, since the COB molecule is the special 
receptor for MHC class I molecules. After recognition, COB + T cells are able to 
kill the cell presenting the endogenous antigen [23,34]. Neither class I nor class 
" MHC molecules can distinguish between 'self' and 'non-self' [35,36]. 
It must however be noted that the preferential association of exogenous 
antigens with MHC class" molecules and endogenous antigens with MHC class 
I, is not an absolute dogma [31,37], and that endogenous TAA can therefore 
end up in the MHC class" molecules of tumor cells when expressed. They can 
also end up in the MHC-class " molecules of tumor-infiltrated, professional 
APCs if tumor antigens are released (for instance from necrotic cells) and 
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thereafter taken up by these APCs (fig. 3). 
Fig. 3. A schematic representation of the CMI response towards a group of cancer (ca) cells. Antigen presenting cells, 
In partIcular dendritic cells (DC) take up tumor-assocIated antigens (.J, degrade these and place antigenIc paptldes 
In the groove of either MHC-class II molecules or MHC-class I molecules. These DC stimulate with these antigenIc 
peptldes CD4 + T helper 1 (Th1J cells or COS+ cytotoxic T cells (Tc) raspectivaly. For antibody production lAbs) 
by B cells tB) the generation of T helper 2 (Th2) cells is necessary. 10 the immune reaction there exist suppressive 
forcas here symbolized by Ts cells. 
When antigan-spaclfic Tc cells recIrculate to the tumor they will recognIze tha antigeo-MHC-class t construct on 
the tumor eel!, whereafter they are able to kill the tumor cells, 
When antigen-speclflc Thl cells recirculate to the tumor they will recognize the antfgen·MHC-class II construct 
on tocany present APC, whereafter they start to secrete interferon·,( {'(-IFNI which will activate NK cells and 
macrophagas (mtJ. The lattar will produce In thesa clrcumstances lathal amounts of oxidative radicals and nitric 
oxide (NO). 
The complex of MHC molecule-antigenic peptide-T cell receptor (TcR) is 
insufficient for an adequate activation of the T cell (fig. 2). For full activation, 
the interaction of other accessory molecules on APC with their ligands on T 
cells is needed, such as the interaction of adhesion molecules [38-40J. The 
binding produced by these adhesion molecules predominantly strengthens the 
interaction between the MHC-antigenic peptide-TcR interaction, but also 
transduces signals that activate the T cell. Important adhesion molecules are 
Leucocyte Function Antigen 1 (LFA-1) that interacts with Intercellular Adhesion 
Molecule 1 (lCAM-1), and Leucocyte Function Antigen 3 (LFA-3) that interacts 
with CD2. Inhibition in this process by monoclonal antibodies to either one of 
these adhesion molecules inhibits the activation and clonal expansion of T cells 
[38J. 
Apart from the adhesion molecule-ligand interaction, the interaction of so-called 
"costimulatory molecules" on APCs and T cells is essential for further T cell 
activation and T cell clonal expansion. Costimulating signals are predominantly 
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provided by the binding of the B7-1 (CDBO) molecule on the APC to the CD2B 
molecule on the T cell (fig. 2) [41,42]. Additional binding of T lymphocytic 
CTLA-4 (Cytolytic T lymphocyte associated antigen) to B7-2 (CDB6) molecules 
on the APC also takes place but it occurs probably later in the process, since 
CTLA-4 is primarily seen on the T cells after activation [43]. If these co-
stimulatory signals are not provided, the result is T cell anergy (a state of 
specific non-responsiveness of T cells) [44]. Hence to avoid a state of T cell 
anergy for a tumor, it is needed that the tumor cell expresses a full picture of 
the costimulating molecules or that the tumor is sufficiently infiltrated with 
professional APCs, such as the DC (fig. 3). 
Functional impairments of T lymphocytes in HNSCC 
The first reports on immunological disorders in HNSCC addressed total 
lymphocyte counts in peripheral blood. A decreased number of circulating 
lymphocytes was associated with the presence of a head and neck cancer and 
correlated with a poor prognosis; later studies made it clear that the total 
lymphocyte count was a poor predictor of prognosis, but rather reflected the 
general status of the patient [45]. Furthermore, both decreased and normal B-
cell numbers have been described in head and neck cancer patients, and an 
evaluation of lymphocytic subsets seems to be of little relevance [45]. 
A number of investigators have considered it a favorable prognostic factor if a 
solid (head and neck-) tumor is densly infiltrated with T cells [46-4B1. However 
this positive relationship has not been confirmed in later large scale studies, and 
other studies have contradicted these earlier findings in HNSCC and other 
tumors [49]. Similarly, a number of studies have tried to correlate the presence 
of various specific lymphocyte subsets in the tumor to prognosis, again with 
conflicting results. Snyderman [50] found that tumors with a low CD4/CDB 
ratio in the tumor infiltrate had less extensive disease, while Wolf [51] observed 
a significantly longer survival in patients with a denser CD4 + T cell infiltration. 
In another study by Wolf [52] on lymphocyte subsets in peripheral blood, an 
increased T4/TB ratio was correlated with advanced tumor stage, but others 
[53] were unable to observe any correlation between intratumoral T cell subsets 
and prognosis in HNSCC. It is worthy to note that the distribution of T cell 
subsets in peripheral blood does not correlate with that in tumor infiltrates [50]. 
T cells infiltrating into a tumor area, may respond to the TAA or to antigens 
induced by an infection or inflammation associated with tumor growth. With 
the evolvement of new techniques like the polymerase chain reaction (PCR) and 
reverse transcribed polymerase chain reaction (RT PCR), it has become possible 
to analyse the molecular structure of T cell receptor gene arrangements. 
Recent studies have made it increasingly clear that TILS in head and neck 
squamous cell carcinomas are at least partly composed of tumor cell-specific 
CD4 + T lymphocytes and CDB + T lymphocytes [54,55], and that unique T cell 
populations are cion ally amplified, which could be the result of an antigen driven 
selection [56]. 
However, if such TAA specific T cells do exist in tumors why is it that when a 
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tumor becomes clinically evident, that the immune system has failed to 
eliminate the cancer cells? To shed more light on this dilemma, it is of relevance 
that functional impairments of lymphocytes in HNSCC have been well 
documented over the past two decades without providing a direct answer to 
this question. In vitro, peripheral blood lymphocytes of healthy individuals 
proliferate when stimulated with Concanavalin A (Con A) or Phytohemagglutinin 
A (PHA). This mitogen response has been shown to be decreased in HNSCC 
patients and the severity of this impairment is correlated to tumor stage 
[57-63]. More recent studies on functional T cell impairments have focussed 
on the ability of T cells to lyse cancer cells. TILs isolated from HNSCC and 
other tumors have poor cytolytic function immediatly after isolation. However 
after in vitro culture of the same cells in the presence of interleukin-2 (lL-2), 
these cells are potentially capable of eliminating tumor cells [64-69]. 
Progressive cancer has been associated with a diminished production of IL-2 
and other cytokines by TILs as well as by lymphocytes from regional 
Iymphnodes in HNSCC and other tumors [63,70,71]. Other functional defects 
in the pathway of target cell killing by cytotoxic T cells have been postulated 
as contributary to the inability of the immune system to erradicate cancer cells 
in general and HNSCC cells specifically. These functional defects include 
a) defects in the function of professional APC (see below), 
b) the production of immunosuppressive factors like TGF-p by the tumor [72], 
c) a down regulation of cell surface molecules (71] important in the T cell-target 
cell interaction like intercellular adhesion molecule·1 (lCAM-1), FasfAPO-1 
(molecules involved in apoptosis), and the 87-1 and 2 (CD80fCD86) molecules, 
or 
d) a poor expression of MCH class I molecules by cancer cells [1,73]. 
Little is known about the relevance of these findings, and especially in HNSCC 
few reports address this matter. 
Natural Killer cells in HNSCC 
Apart from CD3 + T cells there is yet another subset of lymphocytes important 
in a cell mediated reaction against cancer cells. These are the natural killer (NK) 
cells (fig. 3). NK cells are lymphocytes with distinct morphological and 
functional properties. Their cell surface lacks the expression of CD3, CD4, and 
CD8 surface antigens, but expresses CD6, CD16, and CD56 antigens through 
which NK-cells can be identified using monoclonal antibodies. NK-cells recognize 
empty MHC molecules (MHC molecules not loaded with peptide) for target cell 
interaction, and it is unknown which determinants on the tumor cells cause 
activation of NK-cells. Direct contact with the target is necessary for target 
cell lysis through membrane perforating molecules [74]. Most human tumors, 
including HNSCC, are relatively NK-cell resistant, and NK·celis are rarely present 
in tumor biopsies [64,66,71,75,76]. In head and neck cancer, high peripheral 
NK-cell activity, which has been defined as the ability of lymphocytes to lyse 
tumor cells in vitro without the need for activation, has been correlated with a 
prolonged disease free survival, and it has been reported that patients with low 
NK-cell activity had a higher risk of developing metastasis [76,77]. NK-cell 
activity is often considered to play a more important role in control of 
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metastatic disease than of local disease [44,68,75J. Recent in vitro studies 
[64,69J have shown that in contrast to resting NK-cells, IL-2 activated NK-cells 
are capable of killing HNSCC cell lines and entering HNSCC spheroids (which 
are an in vitro model for in vivo growing tumors) as well as HNSCC implanted 
in immune deficient mice. The clinical relevance of these findings is however 
not yet known. 
Macrophages and dendritic cells in HNSCC 
Macrophages and DC mainly originate from blood monocytes that have lineage 
restricted precursors in the bone marrow [78]. The majority of monocytes in 
the peripheral blood express CD14 antigens on their cell membrane, by which 
they can be identified using anti-CD14 monoclonal antibodies. Once 
differentiated into macrophages and DC in organs and soft tissues, they lose 
this marker. Macrophage and DC recruitment is an important phenomenon in 
CMI, and specific adhesion molecules and chemokines are essential to initiate 
chemotaxis. A potent chemoattractant for monocytes is complement factor C5a 
[79,80]. Factors which activate and attract monocytes are leukotriene L TB4, 
cytokines like TNF-a, TGF-~, GM-CSF and M-CSF, and various chemokines [5, 
80-86J. Major chemokines for monocytes are MCP-1, MCP-2, MCP-3, RANTES, 
MIP-1a and MIP-1 ~ [87J. 
Macrophages can be activated by bacterial products or cytokines, and 
contribute directly to tumor cell killing (fig. 3). Their main function is 
scavenging via phagocytosis and pinocytosis. The secretion of cytokines like 
TNF-a, IL-1, and IL-6 and the production of oxygen and nitrogen metabolites are 
also important in scavenger function [88J. The exact role of macrophages in 
tumor control is unknown. Tumor infiltrating macro phages (TAM) are not only 
known for their cytotoxic/phagocytic capabilities, but also to produce factors 
that enhance tumor growth [88]. The number of TAM have been linked to 
enhanced tumor growth in murine sarcomas and carcinomas [89J. On the other 
hand, other studies have indicated that a large number of macrophages within 
a tumor was linked to a favorable prognosis [45,90J. 
Functional impairments of both macrophage and monocyte function have been 
documented in head and neck cancer patients. Cameron [91 J reported a non-
toxicity of macrophages towards tumor cells in a majority of HNSCC patients, 
a phenomenon also documented for other human tumors [92,93J. With respect 
to monocytes, Garraud [94J reported a decreased expression of HLA-DR (class 
II) antigens, and a decreased capability to secrete IL-1 when stimulated with 
LPS. It has also been extensively documented that the monocyte chemotaxis 
of peripheral blood monocytes of HNSCC patients is impaired [95-99J. The 
reduced chemotactic capabilities are attributed to a low molecular mass factor 
with structural homology to p 15E, the capsular protein of murine and feline 
leucemogenic retroviruses, an analogue of which may be produced by HNSCC 
(see below) [100,101 J. Removal of the tumor results in a restoration of 
monocyte chemotaxis, as measured by the monocyte polarization assay [1 02J. 
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DC are the most potent, professional antigen presenting cells in the immune 
system, vital for T cell mediated immunity [24,78]. DC are unique APC in that 
they are the only APC that are able to effectively stimulate naive (CD45RA +) 
Tcells [103-105]. Recent investigations lead to the idea that the DC population 
is heterogeneous with respect to ontogenety [106]. It is certainly 
heterogeneous with respect to morphology, the expression of adhesion 
molecules and in cytokine production [107-110]. With regard to ontogenety, 
part of the DC populations is monocyte-derived and closely associated with 
macrophages, while other DC may have a separate precursor [111]. DC are 
found in virtually all tissues and organs of the body. The DC of the epidermis 
and dermis is known as the Langerhans cell. Langerhans cells contain peculiar 
Birbeck granules that are not seen in DC in other organs, apart from the 
thymus. Langerhans cells of the skin and DC of the gut-wall are considered as 
early (immature) stages in the differentiation of the cell, with an excellent 
capacity to pick up antigens and to degrade these to antigenic peptides and 
place these peptides in the groove of the MHC-molecules. Skin Langerhans cells 
and gut DC have been shown to migrate into the afferent lymph as veiled cells 
to the skin- and gut-draining Iymphnodes [24]. These cells can be seen as 
interdigitating cells in the T cell-areas of these draining lymph nodes, and these 
stages of the DC are considered as mature stages of the cell with an excellent 
capacity to stimulate T cells [112]. It seems likely that DC from other peripheral 
structures, including HNSCC may undergo similar migration and maturation (fig. 
3). 
Whereas macrophages are a clear source of cytokines like interleukins 
(ILl. such as IL-l, IL-6, and TNF-o:, DC have been shown to produce the mRNAs 
of these cytokines, without a noteworthy production of the actual products 
[111,113,114]. In general DC are regarded as poor producers of cytokines, and 
their excellent APC function lies probably in their migratory capacity, their 
capability to form clusters with T cells via adhesion molecules [115,116] and 
their high expression of costimulatory molecules such as B7-1 and B7-2 (CD801 
CD86) [117]. 
DC playa role in tumor immunity by presenting TAA to naive T cells. There are 
no specific monoclonal antibodies that stain for DC's, but a combination of 
semi-specific monoclonal antibodies, like S100, CDla, RFD-l or L25 together 
with morphological characteristics readily identifies human DC. 
A dense infiltration of a tumor with DC has been linked to a favorable prognosis 
in carcinomas of the stomach [118-120], lung [121], bladder [122], esophagus 
[123], and uterine cervix [124]. Less work on HNSCC has been done regarding 
this subject, but similar prognostic correlations were found for nasopharyngeal 
carcinoma's [52,125-127] and laryngeal carcinoma's [128]. With regard to 
functionality of these locally accumulated DC again, defects in DC function 
have been described in animal tumor models, and HNSCC. Gabrilovich [129] 
showed that DC isolated from tumor-bearing mice showed a reduced ability to 
induce a cytotoxic T cell response in healthy control animals, while DC from 
control animals significantly increased specific cytotoxic T cell responses in the 
tumor-bearing mice. In a study of 44 HNSCC patients, Tas [94] found that in 
26 the capability of DC prepared from peripheral blood to form cell clusters with 
allogeneic lymphocytes was reduced compared to healthy controls. This 
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impairment could be restored in vitro by the addition of the calf thymus extract 
thymostimulin (TP-1). 
Table III. Head and neck cancer·derived (serum)factors and their reported effects on various cells 
of the eMf. 
> 75 kd serum factor 
IS 
lAP 
p15E-like factors 
phospholipid 
metabolites 
(pGE2) 
TGF·p 
IL-l0 
GM·CSF 
> 30kd factor 
in superna-
tant of PC I-50 
T cell 
function 
.j, 
.j, 
.j, 
.j, 
.j, 
THI :.j,/TH2:t 
.j, (indirect) 
t 
NK cell 
fUnction 
.j, 
.j, 
.j, 
t 
LAK cell 
functions 
monocyte! 
macrophage 
functions 
t 
dendritic 
cell functions 
IS = immunosuppressive substance, lAP :=: immunosuppressive acidic protein, TGF·1l = transforming growth factor-p, IL-1 0 
= Interleukin-10, GM·CSF = granulocyte macrophage colony slimulating factor, pel-50 = head and neck cancer tumor cell 
liM, blank spaces = not tested. 
Tumor-derived factors influencing the CMI In HNSCC (table III) 
Many factors influence the immunesystem in head and neck cancer. These can 
be divided into a group of factors related to the presence of the tumor per se 
and a group of factors related to the life style of HNSCC patients or their 
treatment. This latter group includes, amongst others, the use of alcohol, 
smoking habits, malnutrition, age, general health status, anaesthesia, surgery, 
and radiotherapy [130,131]. These latter factors have recently extensively been 
reviewed by Wustrow [1311, and will not be discussed here. 
With regard to the first group of factors it has been recognized for a long time 
that the sera of HNSCC patients contain molecules that suppress the CMJ. In 
1978, Berlinger [132J described a deficient mixed leucocyte reaction, which 
was related to immunosuppressive qualities of macrophages. Wanebo [133], 
found that approximately half of HNSCC patients have factors in their sera that 
suppress both lymphocyte proliferation, and NK- and Iymphokine activated killer 
(LAK) cell activity. These factors were not further identified, but may include 
a soluble factor produced by the tumor with a molecular weight of > 75 kD 
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[134]. Immunosuppressive Substance (IS; - 52 kD), and immunosuppressive 
acidic protein (lAP) both suppress PHA-induced human lymphocyte 
blastogenesis, and have been found in serum of head and neck cancer patients 
[135,136]. However their role in the regulation of the immune respons has not 
been thorougly investigated, and they have mainly been suggested as a tumor 
marker. Reports on these factors are lacking in the more recent literature. 
Extensive work has been done on the so-called "p15E-like factors". Cianciolo 
[137,138] was the first to demonstrate the presence of an immunosuppressive 
low molecular mass factor (LMMF; < 25 kD) in both animal and human cancers. 
This protein shows structural homology with the transmembrane (TM) envelope 
protein p15E of animal retroviruses, and is referred to as "p15E", "p15E-like 
LMMF's: or "TM factors". The TM factors can be demonstrated in the sera of 
HNSCC patients [101,139,140], but are certainly not specific for this disease. 
In case of other human cancers, as well as a benign diseases like chronic 
purulent sinusitis and Graves disease these TM factors are also present in 
patient sera [141-143]. Although it is not exactly known, how and where these 
factors are produced, it is assumed that chronicly stressed, or malignant 
transformed epithelial cells of the upper respiratory tract are responsible for 
their production [144]. Also, these p15E-like factors can be extracted from 
HNSCC [101], and the tumors stain positively with a number of monoclonal 
antibodies directed against retroviral p15E [145]. The AA sequence mainly 
responsible for immunosuppression in retroviral p15E has been identified as a 
17 AA long stretch (CKS-17) and this immunosuppressive epitope (CKS-17 
epitope) of retroviral p15E has also been found in HNSCC specimen [145,146]. 
However the CKS-17 sequence is not specific for p 15E, and it does also occur 
in IFN-a [147]. It must be noted that HNSCC also stain for monoclonal 
antibodies specific for IFN-a [147]. 
A number of effects on the immunesystem that are mediated by 
immunosuppressive p15E and CKS-17 are known to date. The molecules 
suppress the chemotactic capability of peripheral blood monocytes 
[100,101,148] and the capacity of DC to form cell clusters [143]. 
Furthermore, the factors suppress monocyte-mediated killing [149], NK-cell 
activity [150], cytokine dependent T cell proliferation [151-153], and 8-cell 
activation [154], mostly through causing an imbalance of cytokine production, 
and consequent disturbance of cytokine mediated signal transduction 
[155-160]. The cytokine dysregulation influences the CMI in many more ways 
than here described, and we are still far from a full understanding of the 
importance of p 15E-like TM factors in head and neck cancer. 
Another important mediator in the immune system that has attracted attention 
in HNSCC is prostaglandin E2 (PGE2). PGE2 is a product of the cell membrane 
phospholipid metabolism with a number of known immunosuppressive qualities, 
including suppression of lymphocyte proliferation and mitogen responses, 
cytokine production by T helper cells, suppression of activated CD8 + T cell, 
NK- and LAK cell activity, and suppression of macrophage functions like 
cytotoxicity and cytokine production [161-168]. PGE2 is probably produced by 
both tumor cells and tumor infiltrating cells [169-171]. As is the case with 
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other immunomodulating factors in head and neck cancer, the role of PGE2 in 
tumor control is unclear. Although it exerts immunosuppressive effects, 
increased levels of PGE2 have actually been associated with improved survival 
and were considered to be an indicator of an enhanced immune response [172]. 
Furthermore, other phospholipid metabolites, like leukotriene B4 (L TB4) and 
platelet activating factor (PAF) with immune inhibitory properties have been 
isolated from head and neck tumor environments, and may have been produced 
by malignant and/or infiltrating cells [173]. They may have synergistic effects 
to PGE2. 
Immuno-suppressive factors other than IS, TM and PGE2/L TB4 have also been 
demonstrated to be produced by HNSCC and its infiltrating host cells. 
Transforming growth factor-Il (TGF-Il) affects B-cells, NK-cells, macrophages 
and T cells. Although it also has concentration dependent, positive effects on 
the immune system, it generally is immunosuppressive by - amongst other 
mechanisms - interference with IL-1 and IL-2 cytokine pathways and inhibiting 
macrophage activation [71]. HNSCC are also able to release IL-10 which 
inhibits the production/release of mediators from CD4 + T helper-1 cells (T 
helper-1 cells are involved in activating and promoting cellular immunity in 
contrast to T helper-2 cells that are involved in the stimulation of humoral 
immunity, see also fig. 3). It has been shown that the number of CDB + T cells 
in the tumor infiltrate that release IL-10, TGF-Il and PGE2 is reduced in head and 
neck cancers [171]. The same study also reported the release of granulocyte-
macrophage colony-stimulating factor (GM-CSF) by tumor- and infiltrating cells, 
wich is associated with the intratumoral presence of CD34 + GM-progenitor 
cells. These cells were considered by the authors as natural suppressor cells 
which were inhibitory to the proliferation of T lymphocytes [174,175]. 
The above described tumor-derived factors are generally refered to as "immuno-
suppressive factors", and although they certainly have these suppressive 
properties in defined assay systems, immuno-modulation would be a better 
description for they exert their effects on the immune system through very 
complicated, not well understood pathways. The same "immunosuppressive" 
factors may also exert some immunostimulatory functions as well depending on 
the concentration and environment [71,168]. 
HNSCC also secrete immuno-modulating factors that are predominantly 
immuno-stimulatory to the cellular immune response. In a recent study [176] 
it was found that the supernatant of a HNSCC-cell line (PC I-50) promoted 
expression of activation markers of NK- and T cells, and sustained proliferation 
of peripheral blood lymphocytes in culture. NK-cells and T cells cultured in the 
presence of a combination of IL-2 and the PCI-50 conditioned culture fluid 
showed an enhanced antitumor cytotoxicity, while cytokine production by NK-
and T cells was also induced. These immunostimulative qualities were 
attributed to (a) soluble factor(s) > 30kD. Little is known about other HNSCC 
derived immunostimulative factors and studies of these factors are in progress. 
Suffice to say that the above described findings on tumor-derived factors once 
more indicate that the immunomodulating role of the tumor itself and its effect 
on tumor growth and metastatic behaviour is still poorly understood. 
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Aims of the studies described in this thesis 
The majority of reports on the infiltration of lymphoid cells into head and neck 
tumors deal with the infiltration of lymphocytes. Reports on the pattern of 
infiltration of monocytes, macrophages and dendritic cells are scarce. It has 
been described that patients with a dense infiltration of S 1 OO-positive dendritic 
cells in nasopharyngeal carcinoma are likely to survive longer than those 
without [1 I. No such correlation appears to exist, however, between the density 
of lysosome-positive macrophage infiltration in or around tumor nests and the 
prognosis or stage of the tumor [1]. 
The first objective of this study was to give a detailed analysis of the pattern 
of tumor infiltration by macrophages and by dendritic cells into head and neck 
squamous cell carcinoma (HNSCC). The spatial relationship between dendritic 
cells, macrophages and malignant epithelial cells and the spatial relationship of 
these cells to infiltrating T lymphocytes and B lymphocytes was studied as well 
(see chapter 3). 
Patients with HNSCC may show certain deficits in their immune functions. The 
cell-mediated immune system is particularly affected with defects including T 
cell function [2-4], and impaired function of monocytes, monocyte-derived 
dendritic cells and macrophages [5-121. 
Our group has previously reported in detail impairments of blood monocyte 
chemotaxis in HNSCC patients. These monocyte chemotactic defects are 
thougth to be caused by factors of low molecular mass (LMMFs, < 25 kDa] 
produced by the cancer cells and to appear in the sera of affected patients. 
Since LMMFs show a structural and functional homology with transmembrane 
(TM) protein p 15E of animal leukemogenic retroviruses, these substances are 
therefore generally be referred to as "immuno-suppressive p15E-like or TM-like 
LMMFs" [13,14]. 
The second objective was therefore to study the relationship of the 
immunohistomorphological expression of this TM factor in HNSCC cells and the 
pattern of infiltration of macrophages and dendritic cells (see chapter 3). 
In earlier reports our group demonstrated that the abnormal monocyte 
chemotaxis and the defective cluster capability of dendritic cells in HNSCC 
could be restored in vitro by the addition of a thymic peptide preparation called 
thymostimulin (TP1) [11]. Clinical trials investigating the effect of TPl in various 
malignant disorders have since been carried out. T-Iymphocyte levels were 
found to increase in patients with malignant melanomas and clinical outcomes 
could be improved with adjuvant TPl treatment [15]. In cases with large head 
and neck cancers overall response to chemotherapy improved if TPl was used 
as adjuvant therapy [16], while peripheral T cell counts improved under the 
influence of TPl in patients with Hodgkin's disease [17]. 
These in vitro observations were the impetus to conduct a double-blind, 
placebo-controlled multicenter study to define in vivo effects of TPI treatment 
on monocyte chemotactic functions, cluster capability of dendritic cells and 
levels of serum p 15E-like or TM factors in HNSCC patients (third objective). 
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The studies were in the setting of a dose finding approach. The in vivo effects 
of TPI treatment described in this thesis are on: 
the disturbed monocyte polarisation and dendritic cell clustering in HNSCC 
patients (chapter 4 and 6); 
the infiltration pattern of lymphocytes, macrophages and dendritic cells in 
HNSCC (chapter 5); 
the levels of p 15E-like low molecular mass factors in peripheral blood of 
HNSCC patients (chapter 4 and 6). 
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Abstract. A study was undertaken to help us reach a better 
understanding oCtile tumor-infiltrating pattern of lymphoid 
cells and in particular of monocyte-derived cells, namely 
the CD68+, acid-phosphAtase-expressing scavenger mac-
rophages and the MHC-c1ass-II- and SlOO-antigen-pre-
senting dendritic cells in head and neck squamous-cell 
carcinoma. In the stroma of the tumors distinctive small 
fields of lymphocytes were found, the T cell areas of these 
fields being intermingled with dendritic cells. Intra-epithe-
lial dendritic cell infiltration was low. The infiltrative pat-
tern of macrophages was similar to patterns described in 
earlier studies with substantial stromal invasion and incon-
sistent intra-epithelial invasion, but small granuloma-like 
structures of CD68+ macrophage-like cells, found in the 
stroma of tumors, have not been reported before. The his-
tochemical localization of the tumor-infiltrated dendritic 
cells and macrophages supports the view that the fomler 
cells are involved in the sensilization to tumor antigens, 
whereas the latter cells are involved in tumor cytotoxic-
ity/scavenging of tumor cell debris. Although it has been 
shown in the past that transmembranal (TM) factors 
(pI5E-like factors) present in the serum and tumor of 
patients with cancer of the head and neck have suppressive 
effects on monocyte/macrophage/dendritic cell function, a 
relationship between the intensity of epithelial staining for 
TM factors and the infiltrative pattern of monocytesJmac-
rophagesJdendritic cells could not be demonstrated. 
Key words: Macrophages - Dendritic cells - Head and 
neck cancer - Squamous-cell carcinoma 
Introduction 
There is experimental evidence that the cell-mediated im-
mune system plays an important role in thedcfence against 
Correspondence to: J. D. Kerrebijn. Depl. of Otolatyngologyn-lead and 
Ned: SUrgery, Unh'mi(y Hospital Dijkzigt. Or. Molewaterplein 40, 
3015 GD Rotterdam, The Netherlands 
hel\d and neck squamous carcinoma cells [4, 8, 9, 15.22). 
Cell-mediated immune functions are executed by T lym-
phocytes, monocytes. macrophages and dendritic cells. It is 
therefore of relevance that defects in the function of these 
cells have been described in palients with head and neck 
cancer. 
Dendritic cells playa role in tUlllor defence by pre-
senting tumor-associated antigens to the immune system. 
Dendritic cells are monocyte-derived cells, with a dislinc-
Ih'e morphology and a characteristic marker pattern in 
immunohistology. The cell shows long cytoplasmic veils 
or dendrites, has a kidney-shaped nucleus and usually re-
acts strongly with MHC-c1ass-ll-directed antibodies 
amongst which are L25 and RFD I. The cell is also often 
positive for the protein SIOO. Dendritic cells have a weak 
expression (sometimes only in the form of a paranuclear 
spot) ofCD68, CDI4 and of the enzyme acid phosphatase. 
To execute its antigen-presenting function, the dendritic 
cell fonn's clusters with lymphocytes and it is therefore of 
importance that, in patients with head and neck cancer, 
the capability of blood dendritic cells to form clusters 
with allogenic lymphocytes has been described as im-
paired (19J, 
Macrophages are also monocyte-derived cells and 
mainly have a killer and scavenger function. Macrophages 
are strongly positive for CD68, and the enzyme acid 
phosphatase; occasionally, they are positive for MHC 
class II markers. Morphologically, they are large, rounded 
cells lacking long cytoplasmic protrusions. Defects in the 
turnoricidal capacity of macrophages have also been re-
ported in patients with head and neck cancer (4]. 
The majority of reports on the infiltration of lymphoid 
cells into head and neck tumors deal with lhe infiltration of 
lymphocytes. Reports on the pattern of infiltration of mono-
cytes, macrophages and dendritic cells are scarce. It has 
been described that patients with a dense infiltration of 
S IOO-positive dendritic cells in nasopharyngeal carcinoma 
are likely to survive longer than those without [16). No such 
correlation appears to exist. however, between the density 
of lysosome-positive macrophage infiltration in or around 
tumor nests and the prognosis or stage of Ule tumor [16]. 
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Table 1. Monoclonal antibodies 
EpilOpe Antibody Dilution Specificity Source 
RFDI 1:1000 Actil'e dendritic cells and ~ub~et of B cells 
(dass-II-MHC-associated antigen) 
Kindly provided by L. Poulter, london 
l25 
SIOll 
CD6. 
CDI4 
COl 
CDI9 
I: 1000 
1:500 
1:200 
1:500 
1:60 
1:25 
Dendritic cells and B cells Kindly pro\ided by ishII, Sapporo 
Dakopatls, G/oslrop 
Ki-M7 
LeuM3 
Dendriticcells (mainly IntrHpithelial) 
Macrophages (strong cytoplasmic expression) 
Monocytes, macrophages 
Berning, Marburg. Germany 
Becton Dickinson, San Jose, Calif. 
Becton Dicklnson. San Jose, Calif. 
Central Laboratory of the Blood 
Transfusion Servlce, Amsterdam 
Kindly pro\'ided by G. J. Cianciolo 
"'"' CtO-D4 
Immature and mature functional T cells 
B cells 
'F5 1:200 plSE 
The rust objective of this study is to give a detailed 
analysis of the pattern of tumor infiltration by macro-
phages, defined as large rounded cells strongly positive for 
CD68 and CDI4 and by dendritic cells defined as stellate-
shaped cells positive for L25, RFDI and S 100. The spatial 
relationship between dendritic cells, macrophages and 
malignant epithelial cells and the spatial relationship of 
these cells to infiltrating T lymphocytes and B lympho-
cytes was studied as well. 
Carcinoma cells, including head and neck squamous 
carcinoma cells are capable of producing factors that exert 
a variety of suppressive effects on different types of im-
mune cells. Some of these tumor factors also demonstrate 
a suppressive effect on the chemotactic capability of mono-
cytes/macrophages and the capability of dendritic cells to 
form clusters with allogeneic lymphocytes. The factors 
produced show a structural and functional homology with 
a retrovirallransmembranal (TM) protein called pi5E [5], 
hence the name pI5E-like factors. It is not yet clear if any 
relationship exists between the degree ofTM factor expres-
sion in head and neck cancer cells in vivo and the infiltra-
tion pattern of macrophages and dendritic cells in and 
around the malignant cells. We therefore also studied the 
relationship of the immunohistomorphological expression 
of this TM faclor in head and neck squamous carcinoma 
cells and the pattern of infiltration of macrophages and 
dendritic cells. 
Materials and methods 
Po/fmls (llJd Il5sues. Samples of fresh tumor tissue were obtained from 
surgically remo\'ed tumors of 18 patients with squamous-cell carcinoma 
of the head and n«k; 7 carcinomas of the oral cavity, 6 oropharyngeal 
carcinomas, 3 carcinomas of the hypopharynx and 2 of the laryn)l were 
included. Small representative tissue parts of the remo\'ed tumor were 
froun In liquid nitrogen and stored at -SO'C. Tissue was taken from the 
central solid part of the tumor to a\'oid the eff«t of superficial bacterial 
Infection on lymphoid cell infiltration; signsoflnf«tion were not present 
in any orthe IOmor biopsies. 
/mmunohfJl%gy. Serial 6-J.tffi cryostat s«tions were cut and mounted 
on slides, air-dried and fi1ied in acetone. Normal rabbit serum 
(Dakopatts, Copenhagen, Denmark) was added and gently remo\'ed by 
tapping the slides after IS min. The slides w«e thereafter incubated for 
I h at room temperature with the monoclonal antibodies listed In Table I, 
to identify the various infiltrating lymphoid cells. All antibodies were 
diluted In phosphate-buffered saline (PBS), pH 7.4 enriched with 1% 
bovine serom albumin (Sigma, SI. Louis, Mo.) before incubation. After 
incubation the sections were gently rinsed with PBS 10 wash away eueS$ 
monoclonal antibodies for at te.ast IS min and thereafter incubated ;,~ith 
horseradish-peroddase--conjugated rabbit anti·(mouse Ig) serom 
(DakOp3tl~, Copenhagen, Denmark) with 1% human pooled ~rtlm for 
30 min. Subsequently, the sections were rinsed with PBS for aoother 
IS min and stained for peroddase activity with 3.3'-diaminobenzidine 
tetrahydrochloride (Sigma, SI. Louis, Mo.) in PBS containing o.ot% 
H202. The s«tions were rinsed in tap water, counterstained with he-
mato)lyl1n for 30 s, dehydrated and mounted in malinol. All sections 
were additionally tested for acid phosphatase activity with naphthol 
AS·DI phosphatase as substrate and heuzotized pararosaniline as dia-
zonium salt. 
The slides were studied by two of the authors(J. K. and H. D.) using 
a Zeiss light micro$cope at \'arious magnifications. Tumors were studied 
for morphology and lymphoid cell infiltration. 
Cell infiltration was semiquantita\'ely scored as follows: -, no cells 
present; ±. few scattered cells present; +. diffuse compartmental infiltra-
tion by solitary cells; ++, m81ked compartmental cell infiltration with no 
apparent organization; +++, he.avycell accumulation with aclear infiltra-
tion architecture; ++++. mMslve clotting of cells. 
Results 
Studying the immunohistological appearance of specimens 
of head and neck carcinoma, we could clearly make a 
distinction between areas composed of malignant 
squamous epithelial cells (parenchymal tumor nests) and 
areas of surrounding stromal connective tissue. 
In the stromal connective tissue three types of lymphoid 
cell infiltration could be identified: (a) an infiltration by 
scattered and mostly single lymphoid cells. (b) small areas 
of densely packed lymphoid cells with a certain degree of 
organization and (c) small granuloma-like structures. The 
first type of stromal infiltration was the most predominant. 
In the malignant epithelial areas (the tumor nests) there 
was also a scattered infiltration of single lymphoid cells. 
The iI/filtration pallem of scallered, mos/ly sillgle 
lymphoid cells ill/he stromal compartment oflhe If/Illor 
(Table 2) 
Many CD68+ large cells were present, which morphologi-
cally varied from monocyte-like cells to very large, round, 
strongly staining macrophages. A similar pattern of distri-
bution was seen for CDI4+ cells. 
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Table 2. Lymphoid cell infiltration In the stromal compartment and into 
malignant epithelial areas 
Cells 
Dendritic cells 
SIOO 
CD!a 
RFDlfL25 
MlKrophages 
CD68 
CDI4 
Teells 
CD) 
Bcells 
CD19 
Areas of Areas of dense 
scatlered packed 
lymphoid cell lymphoid cell 
intiltration accumulations 
+ ++ 
+ ± 
++ ++ 
Granulo- Cancer 
malous nest 
structures infiltra-
tion 
+ 
+ ± 10+ 
+++ H+ (particularly In ++++ ++ 
++ ++ B cell areas) ++ + 
+{o++ +++10++++ ± 
-10 +++ 
RFDl+ stellate-shaped cells were also clearly present, 
however, generally in fewer numbers than the CD68+ mac-
rophages. The RFD1+ dendritic cells were also positive for 
other MHC class If molecules (as identified with the mAb 
OKla); the cells were, however, less positive for L25 and 
markedly less positive for CDla and the SI00 protein 
(though they were positive). 
The number of scattered single CD3+ lymphocytes 
varied from tumor to tumor, there being no apparent rela-
tionship between CD3+ lymphocyte infiltration and the 
differentiation grade or the tumor. A large proportion of tile 
small round CD3+ T lymphocytes were also positive for 
MHC class II and RFD I. CD 19+ B cells were not present 
in this type of infiltrate. 
Areas 0/ dense, packed lymphoid cells ill the stromal 
comparhllent (Table 2) 
Small areas of dense packed lymphoid cell infiltration were 
present in 8118 of the studied tumor specimens (Fig. I). 
These dense lymphoid cell areas were rnmJomly localized 
and not particUlarly located in the vicinity of, or at the 
borders of the epithelial tumor nesls. Inter-tumoral varia-
tion was extensive, hut intra-tumoral variation was limited 
with respect to the number of such areas. 
The areas of dense lymphoid cells had a certain degree 
of architecture with identifiable areas ofCD3+ T cell accu-
mulation and, in an occasional tumor, a central area of 
CD19+ B cells. These latter areas arc reminiscent of early 
B cell follicles. RFDI + and L25+ stellate-shaped cells were 
strongly represented within the CD3+ T cell areas. In the 
S 100 staining, the presence of dendritic cells within the 
T cell zones was also obvious; CDla positivity was, how-
ever, almost absent in these areas. With respect to the 
central B cell areas it was clear that in particular CD68+ 
and CDI4+ monocytes/macrophages could be identified 
within these areas. 
Granulomatolls siructures within the stromal 
compartmenl (Table 2) 
Granulomatous structures were moslly small and always 
located near the borders of the malignant epithelial areas. 
They were present in 7118 of the specimens studied 
(Fig. 2). The presence or absence of these lymphoid cell 
structures was again not dependent on tumor differentia-
tion, nor was there a relationship with the presence of the 
dense. packed lymphoid cell accumulations. The cells 
fonning the granulomas were strongly positive for the 
macrophage marker CD68, while being only weakly posi-
tive for CDI4. RFDI !lhd L25. T lymphocytes (CD3+) and 
B lymphocytes (CDI9+) were not present within these 
structures. 
Scattered infiltration o/Iymphoid cells ill the 
parenchymal areas o/maligllalll epithelial cells (Table 2) 
CD68+ macrophage infiltration was markedly present in 
most tumors, within the parenchymal areas of malignant 
epithelial cells, though, less than in the stromal areas 
Fig. I. Area of dense CD3 t 'ymphoid cell 
infittra!ion In stromal compartmenl Magnifi-
calion: 36x 
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Fig. 2. Granulomatous CD68+ structure 
within the stromal compartment. Note also 
intratumoral C068+ macrophage innltralion. 
Magnlfication: 36x 
Fig. 3. SIOO· dendrillc cell infiltralion Into 
malignant epithelial area and surrounding 
stroma. Magnincation: A SOx: 8 200x 
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(Fig. 2). The pattern of infiltration between the different 
tumors, but also within an individual tumor was often 
variable. There was a stronger and more diffuse infiltration 
in poorly differentiated tumors, the CD68+ macrophages 
often reaching the central areas of the tumor nests. In 
well+differentiated tumor tissue the infiltration was less 
extensive, the CD68+ Illacrophages staying closer to the 
ouler zones of the tumor. A similar pattern of CDI4+ 
monocyte/macrophage infiltration was found although 
numbers of such mOllocyles/macrophages were consider-
ably lower. Very fewCDla+, RFDI+ and L25+cells with a 
classic dendritic cell morphology were present in well-
differentiated malignant epithelial areas; however, in 
poorly differentiated tumors morc RFDI+ cells were iden· 
tifiable. The few infiltrating dendritic cells in the well· 
differentiated tumors stayed at the borders of the tumor 
nests. Intra·epithelial infiltration of 5 l()()+ dendritic cells 
was considerable and comparable (0 stromal SHX)+ den· 
dritic cell infiltration (Fig. 3A, B). 
CD3+ lymphocytes also basically infiltrated the outer 
zones of the tumor nests (similar to the CDla+, RFDI+ and 
L25+ dendritic cells in the well·differentiated tumors), 
again in considerably lower numbers compared to their 
infillratioll into the stromal compartment. Infiltration or 
CD3"" lymphocytes into poorly differentiated tumors was 
more extensive than into well-differentiated tumors. 
CDI9"" B cells were virtually absent from these malignant 
epithelial areas. 
In all tumors, the malignant epithelial structures stained 
clearly positive for the anti·pl5Eantibody 4F5 to an extent 
that mostly depended on the differentiation grade of the 
tumor. Expression varied from weak to strong between 
tumors and sometimes even within tumors. There was, 
however, no relationship between the intensity of pI5E 
expression and the severity of lymphoid cell infiltration of 
any kind. 
Discussion 
The dendritic cells in Ihe antigen·presenting accessory cell 
par excellence [2, 10, II]. The cell exposes on its long 
cytoplasmic extensions a high density of MHC class I and 
II molecules (the antigen-presenting molecules), and ac· 
tively seeks contact with surrounding cells including IYIll' 
phocytes to present the antigens. During this antigen pre-
sentation the cell forms celJ clusters with the lymphocytes. 
Apart from this cluster formation, in which a micro·en-
vironment suitable for antigen presentation is created, the 
dendritic cell is capable of producing a series of cytokines 
that activate T and B lymphocytes. Dendritic cells do not 
only occur in the T cell areas of spleen and lymph nodes a<; 
so-called interdigitating dendritic cells, but also occur as 
the Langerhans cells in the epidemlis and dermis of the 
skin and mucosal surfaces. It is now generally accepted 
that the dendritic cells of the skin and mucosal surfaces 
travel via the lymph to the draining lymph nodes, trans-
porting antigens from the periphery to the lymphoid organs 
to present the antigens to lymphocytes to initiate immune 
reactivity in the lymphoid spleen [12J .. 
Although no specific I11Ab for the staining of dendritic 
cells exists, RFDI and L25 can be used adequately (togeth-
er with classical morphological characteristics such as 
shape) to identify the lymphoid dendritic cells present in 
the T cell areas of spleen and lymph nodes. S 100 tlnd COl 
are reasonably characteristic for the L1ngerhans cells ofthe 
skin (these marker proteins are also present in some den· 
dritic cells of the lymphoid tissues). 
In this study we found that RFD1"" and L25+ dendritic 
cells were markedly present within the T cell areas of Iym· 
phoid cell accumulations present in the stromal compart-
ment between tumor nests. These dendritic cells were vir-
tually negative for the markers Sioo ami COl. The posi-
tion of these lymphoid dendritic cells indicates (heir an· 
ligen-presenting function and suggests an active stimula· 
tion of the imlllune system in the dense lymphoid areas in 
at least some tumors. RFDl"" and L25+ dendritic cells were 
also diffusely present in the stromal compartment, but only 
scarcely within the well·differentiated malignant epithelial 
areas. The intra·epithelial infiltration of 5100· dendritic 
cells was considerable and comparable 10 stromal Sl(}()+ 
dendritic cell infiltration. This observation is in agreement 
with the classical notion that intra-epithelial dendritic cells. 
often referred 10 as Langerhans cells. are mainly SIOO-pos-
itive, and our data thus suggest a more Langerhans·cell· 
like characteristic orthe dendritic cells that have infiltrated 
the malignant epithelial cell areas. 
Our observations are hence by and large in agreement 
with the study of Nomori et al. (16] on nasopharyngeal 
carcinoma. These authors found SIOO"" dendritic cells pri-
marily located within the tumor nests, and found few of 
these cells in the surrounding connective tissue. Similar 
findings have been reported by Nakano et a!. (14J in 
squamous-cell carcinoma of the uterine cervix; they de· 
scribed that the S 100"" dendritic cells were mainly located 
in between the malignant epithelial tumor cells.]n gastric 
adenocarcinoma Tsujitani et al. [20, 21 J described clusters 
of SIOO"" dendritic cells in the tumor stroma as well as an 
infiltration in between the cancer cells. In allihese studies 
SI(}() only was used to identify dendritic cells, and it is 
therefore difficult to draw any conclusions concerning the 
dendritic cells that are negative for this protein (the major-
ity of the dendritic cells present in T cell areas of the focal 
lymphocyte infiltrates found in our study). It is of impor-
tance to note that all three of the above-mentioned authors 
correlated a marked dendritic cell infiltration with a better 
prognosis. These findings indicate that dendritic cells prob-
ably playa more important role in the inunune defense 
against cancer than do scavenger macrophages. The num-
ber of patients and length of follow-up period in our study 
are so far insufficient for correlation studies, but later re· 
ports will address this issue. 
Macrophages with a scavenger and cytotoxic function 
are mainly involved in the efferent arm of the immune 
response. Such cells are markedly positive for CD68 and 
lysosomal enzymes such as acid phosphatase. In our study 
CD6S"" macrophages were strongly represented both 
within the connective tissue compartment as well as in the 
malignant epithelial areas; however, the infiltration into the 
latter area varied widely between the various tumors, some 
showing hardly any, others showing massive inlra·epitheli-
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at invasion. The latter pattern may indicate a strongercyto+ 
toxic response to these tumors; however, histologically 
clear tumor cell destruction was not seen. 
Ki·M7 (a monoclonal antibody that reacts with CD68, 
used in our study) stains mature CD68+ macrophages [7]. 
Despite the fact that macrophages have in vivo and in vitro 
a cytotoxic/cytolytic effect when activated by Iymphokines 
or bacterial products, their precise role in tumor immunol-
ogy in vivo remains uncertain. Cameron and Stromberg [4J 
found a derect in tumoricidal capacity in head and neck 
cancer; half of the patients in their study possessed macro-
phages that were non-cytotoxic toward tUlllorcells in vitro. 
Allen [I] found no histological evidence for a cytotoxic 
role of macrophages in colorectal tumors. In murine sar-
comas and carcinomas. tumor-associated macrophages 
were evell thought to stimulate tumor growth [13]. It has 
been suggested [17] that tumor cells may become insensi-
tive to cytolysis in vivo by activated macrophages by 
building up a resistance to tumor necrosis factors, which 
are mediators in the Iymphokille activation of macro-
phages. • 
Neuchrist et a!. [151. also using immunohistology. 
showed that most tumor-infiltrating macrophages are of a 
functionally mature phenotype. The distribution these 
authors described is similar (0 OUr findings. with an exten-
sive stromal macrophage invasion and some infiltration 
into the areas of the malignant epithelial cells (with a wide 
inter-tumoral variation). These authors. however, did find 
(in contrast to us) a correlation between the extent ofC03+ 
lymphocyte infiltration and the infiltration by macro-
phages. Others have also stressed the important role of 
T-cell-activating macrophages in direct tumor defence 
[23]. It must be noted. however. that Neuchrist et a!. used 
markers such as a-HLA-DR. a-Fcy receptors I. n. Ill, and 
Rm3/1 to identify the macrophages. We consider HLA-
DR+ cells not as classical macrophages but. when stellate-
shaped, as dendritic cells; this might explain the discrepan-
cy between our results and those of others. We did find a 
relationship between the infiltration of HLA-OR+ dendritic 
cells and T cells. 
In nasopharyngeal carcinoma Nomori [16] found that 
mo.~t Iysozyme-antibody-stained macrophages surrounded 
the tumor nests although he did not describe the granulo-
matous structures of our study. In the granulomatous struc-
tures present in the stromal compartment close to the tumor 
nests all cells were strongly positive for C068, in fact the 
histology suggests to us that these areas were almost pre-
dominantly composed of large, fused macrophages 
supporting the classically held view Ihat granuloma's are 
mainly involved in the degradation of persistent antigens or 
nOll-degradable materials. A marked intra-epithelial infil-
tration of macrophages in adenocarcinoma of the stomach 
and in breast cancer was found by Tsujitani et al. [20,21] 
and Zuk et a!. (24J. We also, found a marked infillration 
wilh such cells mainly in poorly differentiated head and 
neck squamous-cell carcinomas. 
Cianciolo (6) demonstrated in 1980 the presence of a 
low-molecular-mass (Iow-Mr) factor in both animal as well 
as human cancers. This factor had an inhibitory effect on 
monocyte chemotaxis and appeared later to be absorbable 
by any of three different mAb to a retroviral capsular 
protein, namely pISE. Tan [18] showed that the pl5E-like 
low-Mr factors were also present in Ihe tumors of patients 
with head and neck cancer as well as in the serum of these 
patients. The pl5E-like factors, presently called TM fac-
tors. have a suppressive effect not only on monocyte 
chemotaxis but .also on the function of various cells of the 
immune systeni 1lle factors inhibit IL-2 dependent T cell 
proliferation, they inhibit the blastogenic responses to mi-
togens and antigens, they suppress the natural killer cell 
activity. they hamper the clustering capacity of dendritic 
cells and they suppress the respiratory burst of human 
monocytes. All tumors in our study showed positivity for 
the anti-TM-factor mAb 4F5. However, no relationship 
between plSE expression and any particular infiltrative 
pattern could be demonstrated. In our earlier report we 
were able to correlale tumor infiltration with chemotactic 
ability [3). Important to note is that positive staining of 
cancer cells for anti-TM-factor mAb docs not necessarily 
mean that the tumor produces or secretes these factors. 
Furthermore, recent work in our group (19) has suggested 
that the anti-TM-factor mAb may not be as specific for 
p 15E as was believed earlier: it has been shown that these 
mAb cross-react with interferon a and possibly other cy-
tokines. Future work will address this maUer. 
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Abstract Head and neck squamous cell carcinoma pa-
tients have been characterized by impairments in their 
cell-mediated immune system, particularly by decreased 
chemotactic function of monocyles and impainnenls in 
the function of the monocyte-derived dendritic cells (viz, 
a decreased capability to fonn cell "clusters"). These im-
paimlcnts are thought to be due to immunosuppressive 
(aeloes of low molecular mass released by tumor, the 50-
called plSE-like factors. These suppressive effects of 
pl5-like factors can be neutralized in vitro by thymic pep-
tides, such as thymostimulin (TP1). In a randomized dou-
ble-blind, placebo-controlled multicenter trial in the Nether-
lands, 41 patients with operable head and neck squamous 
cell carcinomas (HNSCC) were treated for 10 days prior 
to surgery with intramuscular TPI in one of three dosages 
(0.5 mg/kg; 1.0 mg/kg or 2.0 mg/kg body weight) or treated 
with placebo. Assessment of monocyte chemotaxis, the 
capability of dendritic cells to foml clusters and the pres-
ence of plSE-like low-molecular-mass factors (LMMFs) 
in serum was perfomled before TPI treatment and on the 
day of surgery. FindingR demonstrated that TPI in a dose 
of 1.0 mg/kg and 2.0 mg/kg resulted in normalization of 
impaired monocyte chemotactic capability. Although the 
cluster capability of dendritic cells after TPI treatment 
improved, values only reached statistical significance for 
the 0.5 mg/kg group. Serum plSE-like LMMF levels were 
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not affected by TPI treatment in any of the patient groups. 
Contrary to expectations we found no correlation between 
elevated immunosuppressi\'e LMMFs and defective mono-
cyte chemotaxis or cluster capability of dendritic cells. 
We conclude that treatment with TPI can improve mono-
cyte chemotaxis in HNSCC patients but an effect on the 
produclion of plSE-like factors by carcinoma cells could 
not be demonstrated. 
Key words Head and neck carcinoma· Immunotherapy· 
Monocytes . Dendritic cells . Thymostimu~in 
Introducllon 
Patients with head: and neck squamous cell carcinoma 
(HNSCC) may show certain deficits in their immune func-
lions. TIle cell-mediated immune system is particularly af-
fected with defects including T-cell function [20, 24, 44], 
and impaired function of monocytes, monocyte-derived den-
dritic cells and macrophages [3, 5, 8, 14, 16,37,43,45]. 
We and others have previously reported in detail im-
painnents of blood monocyte chemotaxis in HNSCC pa-
lients. These monocyte chemotactic defects are thought 10 
be caused by factors of low molecular mass (LMMFs, < 
25 kDa) produced by the cancer cells and appearing in the 
sera of affected patients. These chemotactic defects can be 
mimicked in vivo in animal models as well as in vitro us-
ing healthy donor monocytes exposed to such tumor-iso-
lated LMMFs [4, 36, 38]. Since LMMFs show a structural 
and funclional homology with transmembrane (TM) pro-
tein plSE of animal leukemogenic retroviruses, these sub-
stances are therefore generally be referred to as "immuno-
suppressive pISE-like- or TM-like LMMFs" {9, 38J. 
The function of monocyte-derived, antigen-presenting 
dendritic cells is frequently disturbed in the presence of 
HNSCC. This defect may also be the resull of plSE-like 
LMMFs [43], since such factors in vitro exert a negative 
effect on the ability of dendritic cells to form cellular c1us-
ters.ln general, monocyte-derived dendritic cells are class 
II MHC-positive mononuclear cells with long cytoplas-
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mic extensions that act as excellent accessory cells in illl" FalcheUi et al. (l2}. Calflhymus glands were minced and extracted 
Illune responses [2, 13, 19.26,35]. with ammonium acetate. The e1>(racl was then heated to 70°C. m· 
In an earlier report we demonstrated that abnomlal tered, and precipitated with ammonium sulfate. The precipitate 
monocyte chemotaxis and a defective cluster capability of 
was dissolved in water and subjected to ultrafiltration on an Ami-
dendritic cells could be restored in vitro by the addition of 
a thymic peptide preparation called Ihymostimulin (TPI) 
Table 2 Clinical profiles of patients with HNSCC prior to TPI [43). Clinical trials investigating the effect ofTPI in vaT- treatment (W well differentiated, 1.1 moderately differentiated, P 
ious malignant disorders have since been carried out. T- poorly differentiated, TL total laryngectomy, CR composite resee-
lymphocyte levels were found to increase in patients with tion, P pharyngectomy, PP partial pharyngectomy) 
malignant melanomas and clinical outcomes could be im- Pa- Sox Ago TNM Local- Differ· Planned proved with adjuvant TPI treatment {7]. In cases with tients classifi- ization entia- treat· 
large head and neck cancers overall response to chemo- cation lion ment 
therapy improved if TPI was lIsed as adjuvant therapy grade 
{34], while peripheral T-cell counts improved under Ihe 
Placebo (II :::: 9) influence ofTPI in patients with Hodgkin's disease {25}, 
These various observations were the impetus for us to I 9 46 TlNIMO Larynx M TL 
conduct a double-blind, placebo-controlled multicenter 2 9 51 T3NOMO oropharynx P CR 
study to define in vivo effects ofTPI treatment on mono- 3 .; 67 T3NIMO oral cavity W CR 
cyte chemotactic functions, cluster capability of dendritic 
4 .; 59 T4N2MO hypophamyx P-M TL+P 
5 .; 45 TINIMO oropharynx M CR 
cells and levels of serum plSE-like factors in HNSCC pa- 6 .; 65 T4N2bMO oral cavity M CR 
Henls. 7 .; 67 T4NOMO oral cavity P CR 
8 d 45 TIN2MO oropharynx W CR 
Pallents and methods 9 d 60 TIN2MO oral cavity P CR 
0.5 mg/kg TPI ('I :::: 10) 
Forty·one patients with operable squamous cell carcinoma of the 10 9 62 T4NOMO Oral cavity M CR 
oral cavity. oropharynx, hypopharynx or larynx agreed to partici-
" 
9 61 TINOMO oropharynx M CR 
pate in the trial. All patients met the inclusion criteria listed in 12 d 46 TINOMO oral cavity P-M CR Table I and gave infomled consent according 10 university re- 13 d 56 T2NOMO oral cavity P CR quirementli for human research in The Netherlands. All patients 
were entered randomly in a double-blind fashion in one of the four 14 d 68 TlN2eMO larynx M TL 
following trealment groups: group I - patients receiving placebo 15 d 72 TINOMO oral cavity W CR 
treatment; group II - patients receiving 0.5 mglkg TPI; group IIl- 16 d 52 T3NOMO oropharynx W CR 
patients receiving 1.0 mg/kg TPI; group IV - patients receivIng 17 d 44 T1NOMO oral cavity P CR 2.0 mg/kg TPL To avoid inwsligator bias, TPI in different 18 d 60 TIN2aMO oropharynx P CR dosages or placebo was (double-blind) injected intramuscularly in 
each patient once daily for 10 <:onsecuth'e days prior 10 definith'e 19 9 74 T2NtMO oral cavity W CR 
operation. All injections were well tolerated and no adverse side 1.0 mglkg TP! (11:::: 13) 
effects were seen. Table 2 summarizes the patients' ages and 20 d 61 TJNIMO Oropharynx M CR sexes, tumor locations and differentiations, TNM classification 
and subsequent treatment given. No statistical differences were 21 d 45 TINOM:O oral cavity M CR 
found for age, TNM classification or tumor differentiations. 22 d 70 T3N2MO oropharynx M CR 
23 d 47 TIN2aMO hypopharynx M TL+PP 
Bovine thymic extract (TPI) 24 9 56 T4N2MO larynx M TL 25 d 78 TlNOMO oral cavity W CR 
Thymostimulin was prepared ali a bovine thymic extract using the 26 9 65 T3N2bMO oral cavity M CR 
following procedure described by Bergesi and falchetti [61 and 27 .; 44 T2NIMO oral cavity M CR 
28 9 52 TJNOMO oropharynx W CR 
29 d 66 T4NIMO oropharynx W CR 
Table 1 Inclusion criteria for patients with operable head and 30 d 56 TJNIMO larynx M TL 
ne<:k squamous cell <:arcinomas (HNSCC) for detenninlng effects 31 d 64 T4NIMO tarynx P TL 
of TPI treatment on monocyte polarization, dendritic cell cluster- 32 d 50 T4N2MO hypopharynx P TL+PP ing and serum plSE-like transmembrane factors 
- Untreated squamous cell carcinoma of oral ca\'ity, oropharynx. 
2.0 mglkg TP I (11 :::: 9) 
33 d 67 T4NOMO Oral cavity M CR hypopharynx or larynx, with no evidence of metastatic disease 34 9 58 TIN2bMO oropharynx M CR 
- Curative treatment possible by surgery or surgery combined 
with radiotherapy 35 .; 59 TJNOMO oropharynx W CR 
- No other malignancies 36 d 72 TJN2bMO oropharynx M-W CR 
- White blood count> 4.109/1; platelets> 100.09/1 and hematocrit 37 9 61 T2NOMO oral cavity M CR 
> 30% 38 d 51 nN2cMO larynx M-W TL 
- No serious concurrent non-malignant systemic or infectious 39 d 51 T4N2MO oral cavily M-P CR 
diseases 40 9 49 T3N2bMO oropharynx P CR 
- No treatment with corticosteroids 41 9 31 TINOMO oral cavity W CR 
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con PM-IO membrane. The fillrate was desalted 011 Sephadex G-
25 and gel-filtered on Sephadex 0-50. Fractions showing charac-
teristic bands at RF 0.22 and 0.24 on polyacrylamide gel elec-
trophoresis were combined and lenned "Ihymostimulin" (TPI). 
This extract was next lyophilized and its activity expressed as units 
ofT-cel/-roselle (onnation per milligram of protein. No endotoxin 
was contained in this extract, as tested in doses up to 100 mg/kg 
when administered to mice for 21 days or rals for 31 days, or when 
given to cats or dogs for 180 days in doses up to 50 mglkg (12). 
Additionally, the extract failed to alter neuromuscular transmission 
in vitro or In vivo [6). 
Isolation of peripheral blood monocylcs 
Peripheral blood mononuclear cells from patlenl~ and heallhy con-
trols were isolated by Ficoll-Isopaque density gradient centrifuga-
lion. Cells were washed twice in phosphate buffered saline (PBS) 
at pH 7.4, containing 0.5% bovine serum albumin (BSA). Cells 
were then counted in suspension employing poslthe staining with 
non-spedfic esterase (NSE) as described by Mullink et a!. (29J. 
Monocytes in the Ficoll-Isopaque isolated fraction were enriched 
by Percoll gradient centrifugation [31]. After washing, the Ficoll-
Isolated cell pellet containing both 1II0nocytes and lymphocytes 
was resuspended in RPMI 1640 supplemented with 10% fetal calf 
serum (GIBeD, Breda, The Netherlands), 2 rnAl glutamine and an-
tibiotics (penicillin and streptomycin), and carefully underlaid 
with an equal volume of Percoll 1.063 (Phannacia, Uppsala, Swe-
den). After centrifugation at 400 g for 40 min, all cells were col-
lected from the interface, washed twice in medium for 10 min and 
counted. This latter suspension now contained 70--95% NSE-posi-
live cells. 111is suspension was used for direct monocyte polariza-
tion and maturation to obtain dendritic cells (see below). 
Fomlation of dendritic cells 
Dendritic cells were prepared from blood monocytes according to 
the method described by Kabel el al. (21]. Melrizamide (Serva, 
Heidelberg, Germany) was dissolved in RPMI supplemented with 
10% felal calf serum. Cells from the isolated monocyte fractions 
were exposed to 14.5% metrizamide in suspension culture for 30 
min (using 5% CO! at 37°C and 100% humidity). Thereafter, cells 
were washed by slowly adding culture fluid to prevent osmotic ly-
sis. Cells were then further cultured under non-adhering conditions 
for 16 h in polypropylene tubes (with 5% COl and 100% humidity 
at 37°C), This procedure yielded 40---30% cells with a dendritic 
morphology. showing class II MHC positivity, decreased expres· 
~ion of the monocytic CDI4 detemlinant, decrea~ed phagocytic 
capability, but enhanced stimulator capability in the mixed leuko-
cyte reaction (MlR). The full technical details of this method are 
described by Kabel et al. (21) and in Mooy et al. (281. 
Clustering of dendritic cells 
The cluster assay as described by Austyn et al. (2J was perfomled 
with modifications used by Kabel et al. (2IJ. Approximately 5 x 
I~ dendritic cells prepared from peripheral blood monocytes were 
exposed to melrizamide and allowed to cluster for 4 h in 5% COl 
at 37°C in 250 1-11 flat-bottomed wells. Fonned clusters were 
counted using an inverted microscope and values were expressed 
as the number of c1uslers per 6 microscopic fields (x 200). A clus-
ter was defined as an accumulation of 4-25 cells in three-dimen-
sional configuration. An insufficlent amount of blood was received 
to obtain enough dendritic cells for the cluster assay in 8 cases. 
Monocyte polarization assay 
TIle Cianciolo and Snydennan (IOJ assay for monocyte polariza-
tion was perfonned with slight modil1cations [38J to rapidly test 
monocyte chemotaxis. Outcomes of the assay previously proved to 
correlate well with outcomes of the conventional Boyden chamber 
assay to measure chemotaxis 10 casein (38J. Repeat 0.2 011 aliquots 
of the Percoll or elutriator purified cell suspension containing 
0.2 x 10" monocytes were added to 12-75 mm polypropylene tubes 
(Falcon Labware Division, Becton Dickinson, Oxford, Calif., USA) 
containing 0.05 ml of either medium or fonnytmethionylJeucyl~ 
phenylalanine (f}.1lP) in medium. to reach a final concentration of 
10 nM. All experiments were carried out in duplicate. Tubes were 
incubated in a waterbath at 37°C for 15 min. Incubation was 
stopped by addition ofO.25-ml ice-cold 10% fOffilaldehyde in 0.05 
M PBS (pH 7.2). Cell suspensions were kept at 4°C until counted 
in a hemocytometer under a light microscope (magnifi"ation, x 
250). Each test was read "blindly" by two persons and 200 cells 
were counted from each tube. A cell wa); considered to be "polar-
ized" if one of the following occurred: elongated or triangular 
shapes, broadened lamellipodia or membrane ruffling. 
Chemotactic responsh'eness of a monocyte population was ex-
pressed as the percentage of polarized monocytes in the presence 
of f}.tlP minus the percentage of polarized monocytes in the ab· 
sence of fMlP. The percentage of polarized monocyles was calcu-
lated as follows: 
% total cells polarized 11)0% 
% NSE-positive cells x 
Lymphocytes were excluded by their lack of any polarization ac-
tivity in this assay (9J. 
Detemlination of pl5E-like immunosuppressive factors 
in patients' sera 
Sera for immunological evaluation was collected by venipuncture 
prior to the first injection of TPI and 1-2 h before surgery. In a 
number of events insufficient sera were received due to logistical 
problems. Sera of heallhy hospital staff members served as conlrol 
sera during aillesis. Sera were diluted I: I in saline and subjected 
to ultrafiltration through Amicon CD25 Cenlriflo cones (Amicon 
Corp .• Dam'ers, Maine, USA) for 15 min at 800 g (molecular mass 
"cut-off point", 25 kDa). Residues were resuspended and stored at 
-20"C until further use. 
The capability of serum fractions to inhibit flo"llP-induced po-
larizalion of healthy donor (elutrialor-purified) monocytes was de-
tennined by incubating (I x IO"/ml) healthy donor monocytes for 
15 min at 37°C either with fMlP alone or with fMLP in combina-
tion with a serum fraclion (final dilution, I :60). Details of the 
technique have been described by Tas et al. (43J. The percentage 
of inhibition was calculated as follows: 
i:: (I - (Ff-fo/Mf·fo» x 100%. where Ff:: % monocytes po-
larized after incubalion with (MlP and LMMF; Mf = % Olonocyte§ 
polarized after incubation with f}.ilp, alone; and fo :: % sponta-
neously polarized monocytes. 
Spontaneous polarization was not affected by addition of 
serum fractions to non-flo,,1lP stimulated donor mo-nocytes. 
To validate the pl5E-like character of LMMF adsorption, exper-
iments were carried out by neutraliling serum frac~ions at 4°C for 
16 h before testing effects on monocyte polarizalion by using a 
combination of two pl5E-specific mAbs (4F5 and 19F8 as anti-
pl5E isotypes Ig02a and IgG2b). The final mAb dilution was I: 
200 and finallgG concentration 50 J1g/ml. Following neutralization, 
Amicon ultrafiltration was perfonned to remove complexes. The 
adsorption/neutralizing procedure was carried out twice. As con-
trol antibodies Irrelevant anti-human Jg02a and IgG2b were used. 
Statistical analysis 
Statistical analysis was perfonned using the Wilcoxon signed rank 
test; P < 0.05 was takefl as the level of significance. 
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Flg.l Serum pl5E-like low-
molecular-mass factor 
(LMMF) levels and monocyte 
polarization before treatment 
J elevated serum LMMFs and 
depressed monocyte polariza-
lion; /I elevated serum LMMFs 
and nomtal monocyte polariza-
tion; II/ non-elevated serum 
LMMFs and depressed mono-
cyte poJariulion; IV non-ele-
vated serum LMMFs and nOf-
mal monocyte polarization (. 
pallenlS, 0 healthy controls) 
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Figure I shows prelreatment levels of pl5E-like LMMFs 
in the sera of individual HNSCC patienls in comparison to 
their individual monocyte chemotactic capabilities. Lev-
els of pl5E-like LMMFs in patient sera were detemlined 
indirectly by measuring their suppressive effects on 
fMLP-induced monocyte polarization of healthy blood 
donors. 
In the control group of healthy volunteers the mean 
monocyte polarization was 34.2% ± 7.9 (II = 23), while 
the mean bioactive inhibitory level of pl5E-like LMMFs 
was 7.3% ± 9.3 (II = 23). Monocyte polarization < 18.4% 
(mean -2 SD) was therefore considered to be defective, 
and LMMF levels> 25.9% inhibition (mean + 2 SD) were 
considered elevated. According to these criteria, 16 pa-
tients (40%) had defective monocyte polarization, viz 
chemotaxis of lower than 18.4% towards the chemoattf3c-
tant fMLP prior to treatment. 1\velve patients (31%) had 
elevated pI5E-like LMMF levels. The palients with de-
feclive monocyte chemotaxis were evenly distributed 
over the group that had nonnal serum LMMF levels and 
the group that had elevated serum LMMF levels, and no 
correlation was possible between elevated LMMF levels 
and disturbed monocyte chemotactic capability (II = 35, r = 
0.018, P > 0.1). 
The mean dendritic cell cluster assay in Ihe healthy 
controls was 133.5 ± 42 c1usters/6 microscopic fields (II = 
17). A value of less than 92 c1usters/6 microscopic fields 
(mean - I SD) was considered to be abnonnal. According 
to this criterion 16 patients had defective dendritic cell 
clustering capability before treatmen!. A correlation be-
tween dendritic cell clustering capability and pl5E-like 
• II 
• o 
• 
• 
• • 
• 
• 
% tMlP IoducOO mOl'lO(;}'le polarizatlon 
LMMF levels could not be detected (II = 34, r = --0.10, P > 
0.5). Furthennore no correlation existed between dendritic 
cell clustering capability and monocyte polarization (II = 
34, r = 0.08, P :> 0.5). 
Effects ofTPI treatment on monocyte polarization, 
dendritic cell clustering capability 
and serum pl5E-like LMMF levels 
Figure 2a shows fMLP-induced polarization of mono-
cytes isolated from the blood of HNSSC patients before 
surgery (day 0) and 10 days after surgery (day 10) and ad-
ministration of either placebo or a TPI dosage. In all four 
groups the mean initial value (day 0) was markedly lower 
than the 34.2% mean of the polarized monocytes found in 
the healthy control group. 
Treatment with 1.0 mg/kg TPI resulted in a restoration 
of disturbed monocyte polarization from 17.6% ± 6.3 (11 = 
13) to a near-nonnal value of 30.9% ± 13.8 (1/ = 13) at day 
10 (P < 0.0l). Similar effects were seen with 2.0 mg/kg 
TPI (P < 0.05). Monocyte polarization improved to 
32.0% ± 15.8 (II = 9) from an initial 17.8% ± 18.2 (II = 9). 
Treatment with 0.5 mg/kg TPI showed no significant im-
provement (20.9% ± 7.0 to 23.0% ± 8.1,11 = lO). Placebo 
treatment also showed no significant effect on the im-
paired monocyte polarization (24.0% ± 14.2 to 25.7% ± 
8.3, /I = 9). 
Figure 2b shows the number of clusters formed by 
monocyte-derived den"dritic cells from the sera of HNSSC 
patients. At day 0, patients of all four groups showed 
lower values than nonnal, although this was least marked 
for the placebo group. All three TPI-treated groups 
showed an increase in mean dendritic cell clustering capa-
bility after treatment (0.5 mg/kg group: 86.0 ± 37.0 to 
121.1 ± 38.2, /I = 9; 1.0 mg/kg group: 99.7 ± 34.2 10 116.6 
± 23.0, /I = ll; 2.0 mg/kg group: 98.4 ± 30.5 10 113.3 ± 
23.0, 11 :;:: 9). However, only the change in the 0.5 mg/kg 
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group reached statistical significance (P < 0.05). 111C 
placebo group showed some decrease in the clustering ca· 
pability of dendritic cells, but this decrease was not statis-
tically significant. 
Pretreatment levels of pl'SE-like LMMFs and values 
found after 10 days ofTPI treatment are shown in Fig. 2c. 
No significant changes were found in the levels of serum 
p 15E-like factors in group I (0.5 mg/kg. II ::: 7), group II 
(1.0 l11g/kg, 1/ ::: 15), group III (2.0 mg/kg, 11:::: 9) or pla-
cebo (1/ :::: 9). 
Discussion 
Suppression of cell-mediated immunity in HNSCC is 
thought to be at least partially due to immunosuppressive 
LMMFs produced and released by lumors (9), These fac-
tors show a structural homology to relroviral protein 
p15E. The plSE-like LMMFs and a 17-amino-acid pep-
tide synthesized from MuLV p 15E (anti·CKS~ 17) exert a 
suppressive effect on various immune cells. Suppression 
has been dcmonstrated in vitro on monocyte chemotactic 
responses [9, 36); monocyte cytotoxicity by inactivating 
interleukin-I (IL-I) (15, 22J; the respiratory burst of hu-
man monocyles (17); activation of feline neutrophils [23J; 
IL-2- or IL-I-dcpcndent proliferations ofT-celIs and their 
blastogenic responses to mitogens and allo-antigens [I L, 
30,33), activity of human natural killer "(NK) cells [18]; 
polyclonal activation of B-cells (271 and the capability of 
dendritic cells to fonn clusters per se and with T-cells [32, 
41J. 
The presence of immunosuppressive p15E-like factors 
can be detectcd in the serum of HNSCC patients via a 
bioassay using healthy donor monocytes. In previous 
studies we showed that removal of a tumor offen resulted 
in a postoperative decline of the level of these serum 
pl5E-like LMMPs (42), and restoration of monocyte 
chemotactic responsiveness (36). We assumed that there 
was a direct effect 011 monocyte chemotaxis by immuno-
suppressive pl5E-like LMMFs produced by tumor and 
circulating in serum, since direct contact between mono~ 
cyles and the serum pl5E-like factors seemed inevitable. 
Our present data, however, have failed to demonstrate any 
positive correlations between defective monocyte chemo-
taxis or dendritic cell clustering and serum levels of p15E-
likeLMMFs. 
An explanation for our present findings may be due to 
heterogeneity in sensitivity of monocytes of individual 
HNSCC patients to immunosuppressive effects of p 15E-
like factors. It is also possible that other immunomodulat-
ing factors produced in our patients and stimulating or 
suppressing monocyte chemotaxis may play an additional 
role. A third explanation might be that defective mono-
cyte polarization and dendritic cell clustering might not be 
a direct result of elevated pl5E-like LMMFs in serum, but 
that these immunosuppressive factors could possibly exert 
such effects as hampered maturation of fully active mono-
cytes and dendritic cells at the level of the bone marrow. 
In contrast, healthy individuals may have relatively high 
serum levels of pl5E~like LMMFs without showing clin-
ical or experimental signs of immune suppression (39J. 
Our results do show restoration of defective monocyte 
chemotactic responsiveness in HNSCC patients due to 
treatment wit~ TPI. Treatment wilh 1.0 mglkg or 2,0 
mglkg body weight administered intramuscularly for 10 
consecutive days prior to operation has given near-nomlal 
values for monocyte responsiveness on the day of opera-
tion, Statistically, 1.0 mglkg was found to be the most op-
timal dose for restoration of the monocyte polarization, 
which has also been reported to be the dose most fre-
quently used to treat patients with various olher disorders 
ll, 7, 40J. An improvement of the dendritic cell clustering 
capability after TPI treatment was seen for all TPI-
treated groups; however only in the 0.5 mglkg group did 
this reach statistical significance. A plausible explanalion 
for this may be that the mean pretreatment values of the 
dendritic cell cluster assay of the 1.0 mg/kg and 2.0 mg/kg 
groups were, Jess disturbed than those of the 0.5 mg/kg 
group. Therefore the possible improvement that could be 
achieved was less pronounced. Tas et al. {40) treated pa-
tients with chronic purulent rhinosinusitis and found a 
similar restorative effect-of TPI treatment on monocyte 
chemotactic functions accompanied by a concomitant de-
crease in serum pl5E-like LMMF levels as well as clear 
clinical improvement. 
In our current study, pl5E~like LMMF levels in sera 
from HNSCC patients were unaffected by TPI treatment. 
These findings suggest that TPI counteracts the immuno-
suppressive effects of pl5E-like factors at a cellular level 
and TPI does not affect production of pl5E-like factors 
by tumor. The decrease in detectable serum LMMF levels 
reported in patients with rhinosinusilis after TPI treat-
ment could also be explained by a lower production due to 
improved clinical status, rather than a direct effect ofTPI 
on the production or immunosuppressive properties of 
these p15E-like LMMFs. Conclusions concerning clinical 
effects of TPI in the treatment of HNSCC cannot be 
drawn from our study at this time and will be addressed in 
a later report on the long-tern) results ofTPltreatment. 
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Thymostimulin enhancement of T cell infiltration 
into head and neck squamous cell carcinoma 
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THYMOSTIMULIN ENHANCEMENT OF T·CELL 
INFILTRATION INTO HEAD AND NECK SQUAMOUS 
CELL CARCINOMA 
Jeroen D. KerreblJn, MO, Peter J. SImons, AifonSU8 J. M. 8alm, MO, PhD, 
Moort.n Tas, PhD, Paul P. Knegl, PhD, Nice de Vries, PhD, 
I"g B. Tan, PhD, and Hemmo A. DrexhBge, PhD 
Background. Head and neck squamous cell carcInoma 
(HNSCC) produces Immunosuppressive low-molecular-mass fac-
tors (lMMFs) responsIble for defects In the cefl-mediated Immune 
system. These defects Include ImpaIred monocyte chemotaxis 
and an Impaired capability of dendritic cells (DC) 10 form ceUular 
clusters. II has been shown previously thai the ImmunomodufaUng 
drug thymosllmutin (TP1) restores Ihese deleets In vitro. 
Methods. An ImmunohIstochemical study was performed on 
tumors of 18 pallents with HNSCC who had preoperatively been 
trealed with TP1 In one 01 three dosages (0.5 mg.1<g, 1.0 mglkg, 
2.0 mglkg body weight), Addillonally, tumors of 4 patients who 
had been !reated with a placebo and 12 patients who had not 
received any preoperative treatment were studied. A relative sur-
face area of InfiUralfon, meanIng the percentage of stromal or 
epltheUat tissue covered by InfiltraUng cells In hIstologic sections, 
was calculated usIng an Image analysIs system (VrOAS AT) for 
CD3+ T-cells, CDI4+/C068+ monocytes/macrophages and 
l25+/CDla+ dendritic cells for each tumor. 
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Results. A hIghly Significant, denser T·cell !nfmralfon Into the 
stromal tlssue area of tumors 01 patlents who had been treated 
wilh TPI when compared with tumors of non-TP1·treated pa-
lIenls was obs(HVed lor all three dosages. None 01 the other 
tumor·lnfittratlng 'cell types was aflected by TP1. In addilfon, a 
correlation was found between the tumor T·celt Inmlrallon and 
capabllily of DCs In the peripheral blood to form clusters with T· 
cells. No correlaUon exlsled between CD3+ T·cell numbers In 
peripheral blood and T·tal! Infiltration Into the tumor; nor were 
monocyte chemolacUc functions In peripheral blood correlated 
with lumor Inlmration by monocytes or monocyte-derived macro-
phages and DCs, 
Conc(uslons. Preoperative treatment of HNSCC patients with 
TPI appears 10 strongly enhance lumor-T -celllnfillraUon. The 
number 01 lumor·lnlillraling DCs was nol affected by TP1, but 
a positive correlation between lumor-T-cell Infiltration and DC 
cfustering capability suggests Ihallhe fUnctional status of DOs Is 
Important In Improved cell·medlated Immunity. 
HEAD & NECK 1996;18:335-342 
@ 1996 John Wiley & Sons, Inc. 
The cell-mediated immune system is assumed to 
playa significant role in defense against squa-
mous cell carcinoma of the head and neck 
(HNSCC). It is therefore of interest that abnor-
malities in functional behavior of lymphoid cells 
have been described in these patients, including 
impairments of the function of T-lymphocytes, 
monocytes, and the monocyte-derived dendritic 
cells (DCs) and macrophages. I-8 In previous stud-
ies we reported on defects in monocyte chemotaxis 
and the defective capability of antigen-presenting 
monocyte-derived DCs to form clusters with them-
selves and T-cel1s,4.8-IO Although tumors may pro-
68 Chapter 5 
duce various immunostimulatory and immuno-
suppressive factors, and heretofore-described de-
fects are at least partiy due to an immunosuppres-
sive low-molecular-mass factor (LMMF) produced 
by the squamous carcinoma cells. II Cell-mediated 
immune defects could be induced in vitro afWr 
isolation of the LMMF from the tumor or the se-
rum ofHNSCC patients, and neutralizationexper-
iments showed the factor to belong to the IFN-
alp16E family of immunosuppressive peptidcs. 12 
Thymostimulin (TPl), a thymic hormone prepara-
tion, was shown to counteract the immunosup-
pressive action of these LMMFs in vitro, and to 
restore the migratory capability of blood mono-
cytcs as well 8S the clustering capability of DCs.9 
In vitro and in vivo TPI treatment improved 
the defective monocyte chemotaxis and DC clus· 
tering capability in HNSCC patients. Recently, 
we reported a restoration ofmonocyW chemotactic 
functions and an improvement of DC clustering 
capability on the day of operation of patients who 
had been treated with daily TPl injections for a 
period of 10 days prior to surgery.IO This report 
addresses the effect of TPl treatment on the in-
filtration of T.lymphocytes, monocyteslmacro· 
phages, and DCs into the tumor itself, studying 
the Bame group of patients as referred to above, 
of whom the data on the number and performance 
of peripheral monocytes, DCs, and T-cells were 
available. 
PATIENTS, MATERIALS, AND METHODS 
Patient.. Thirty-four patients with operable 
squamous cell carcinoma of the oral cavity, oro· 
pharynx, hypopharynx, or larynx consented to 
participate in the multicenter study. The study 
had been approved by the medical ethical commit-
tee of all participating centers. All patients met 
the following inclusion criteria: Squamous cell car-
cinoma of the oral cavity, oropharynx, hypophar. 
ynx, or larynx, with no evidence of distant 
metastatic disease. No other malignancies were 
present. Intent of curative treatment by surgery 
or surgery and radiotherapy. A white blood cou'at 
>4.109IL, platelets > 100.091L, and hematocrit 
>30%. Patients had received no previous radio-
therapy or surgery in the head and neck area or 
previous chemotherapy, nor had they been treated 
with corticosteroids. They were without serious 
nonmalignant systemic disease or serious infec· 
tious diseases. 
Twenty-two patients comprised a subpopula· 
tion of a larger study group who had been entered 
in a multicenter, double-blind, placebo-controlled 
trial studying the effects of TPl treatment of 
HNSCC patients. These 22 patients came from 3 
of the 5 participating centers of the larger study 
on the restoration of monocyte chemotaxis and DC 
clustering (dose-finding study). Tumor tissue was 
taken from these 22 patients for immunohisto-
chemistry ~uring surgery. They were, through a 
random and' double-blind selection, entered into 
one of the following four treatment groups: Group 
I, patients receiving placebo treatment (n = 4)j 
group II, patients receiving 0.5 mg TPlIkg body 
weigh,t (Il = 4); group III, patients receiving 
1.0 mg TPlIkg body weight (11 ~ 6); and group 
IV, patients receiving 2.0 rng TPllkg body weight 
(n ~ 8). 
TPI or placebo was injected intramuscularly 
(arm or leg) once daily for 10 consecutive days 
prior to surgical removal of the tumor. The intra-
muscular injections were well tolerated, and no 
adverse side effects were seen. At the time of sur-
gery, blood was drawn for the tests described in 
detail previously9,IO and in short below. An addi-
tionall! patients (group 0) who met the inclusion 
criteria but did not agree to participate in the 
treatment protocol were not treated preopera-
tivelyj however, surgical specimens as well as pe-
ripheral blood cells on the day of surgery were 
studied (these patients had agreed to this type of 
investigation). 
Patients in the various treatment groups were 
comparable for age, TNM classification, and pri· 
mary site of the tumor (Table 1). The number of 
patients in each group depended on the availabil· 
ity of tumor tissue (not all participating centers in 
the larger hial provided tumor tissue), explaining 
the unbalanced number of patients between the 
groups. ,Because the number of patients in the 
respective treatment groups was small, the three 
groups ofTPl-treatedpatientsandthetwogroups 
of non immunologically treated patients were com· 
bined, when appropriate, for statistical evalu· 
atiQn. 
Material. and Methodll. Thymostimulin is a bovine 
thymic extract prepared by Serooo, according to 
Bergesi and Falchettp3 and Falchetti et ai, U using 
the following procedures: calf thymus glands are 
minced and extracted with ammonium acetate. 
The extract is heated to 70"C, filtered, and precipi-
tated with ammonium sulfate. The precipitate is 
dissolved in water and subjected to ultrafiltration 
with an Amicon PM-lO membrane. The filtrate 
is desalted on Sephadex 0-25 and gel-filtered on 
Sephadex G·50. The fractions which on polyacryl-
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Table 1. ClinIcal profiles of pallenls. Samples of fresh tumor tissue were obtained 
Patients TNM classification Site 
from surgically removed primary tumors. Small 
parts of tissue without macroscopic signs of necro· 
Placebo (n = 4) sis, and representative ofthe removed tumor, were 
1 T2N1MO Oropharynx frozen in liquid nitrogen and stored at ~80°C. Se-
2 T4N2MO Hypopharynx rial 6 {tm-cryostat sections were cut and mounted 3 T4NOMO larynx 
on slides, air dried, and fixed in acetone, Normal 
• T3NOMO Oropharynx 0.5 mg TP1/kg (n "" 4) rabbit serum (Dakopatts, Copenhagen, Denmark) 
5 T4NOMQ Oral cavity was added and gently removed by tapping the 
6 T2NOMO Oral cavity slides after 10 minutes. The slides were then incu-
7 T2N2MO Oropharynx bated for 1 hour at room temperature with the 8 T2N1MO Drat cavity 
monoclorialantibodies listed in Table 2, to identify 1.0 mg TP1/1(g (n = 6) 
9 T3N1MO Oropharynx the various infiltrating lymphoid cells. All anti· 
10 T2N2MO Hypopharynx bodies were diluted in phosphate·buffered saline 
11 T2N1MO Oral cavity (PBS) pH 7.4 enriched with 1% bovine serum albu· 
12 T3NOMO Oropharynx min (BSA)(Sigma, St. Louis, MO) and 0.01% azide 13 T4N1MO Oropharynx before incubation. After incubation, the sections 
" 
T4N1MO larynx 
2.0 mg TPI/1(g (n = 8) were gently rinsed with PBS to wash away excess 
15 T2N2MO Oropharynx monoclonal antibodies for at least 16 minutes and 
16 T3NOMO Oropharynx thereafter incubated with horseradish peroxidase 
17 T3N2MO Oropharynx (HRP)-conjugated rabbit anti-mouse serum (Da-18 T2NOMO Oral cavity kopatts, Copenhagen, Denmark) with 1% human 19 T3N2MQ larynx 
20 T4N2MO Oral cavily pooled serum for 30 minutes. Subsequently, the 
21 T2NOMO Oral cavity sections were rinsed with PBS for another 16 
22 T3N2MO Oropharynx minutes and stained for peroxidase activity with 
Untreated (n = 12) 3.3'-diaminobenzidine-tetra-HCL (Sigma) in PBS 23 T4N1MO Oral cavity 
containing 0.01% H20 2• The sections were rinsed 2. T3N2MO larynx 
25 T3N1MO Oropharynx in tap water and counterstained with hematoxylin 
26 T3N1MO Hypopharynx for 30 seconds, dehydrated, and mounted in depex 
27 T4NOMO larynx mounting medium. 
28 T4NOMO Oral cavity Analysis of tissues was done using a Vidas RT 29 T1N2MO Hypopharynx image analysis system (Kontron, Munich, Ger-30 T2NOMQ Oral cavity 
31 T4N2MO Hypopharynx many). At magnification X 200, 6-10 randomly 
32 T4N2MO larynx chosen fields of tumor stroma and 3-7 randomly 
33 T4NOMO larynx 
3. T3N1MO Oropharynx 
Table 2. Monoclonal antibodies. 
amide gel electrophoresis show two characteristic Epitope Antibody Dilullon SpecilJcitylsource 
bands with Rf 0.22 and 0.24 are combined and CDla OKT6 1:100 Dendrillc cells (maInly 
termed thymostimulin (TP1). The extract is lyo- Inlraepithetiat) (kindly 
philized, and its activity is expressed as units of provided by T. Godlhelp. 
T-cell-rosette formation per milligram of protein. Rotterdam) 
It does not contain endotoxin, as tested with the L25 1:1000 Dendritlc cells and B cells (kindly provided by IShii. pyrogen test in rabbits. In toxicologic studies, the Sapporo) 
extract does not cause any toxic or other side ef- CD66 KI-M7 1:200 Macrophages (slrong 
fects in doses up to 100 mglkg when administered cytoplasmIc expression) 
to mice for 21 days or to rats for 31 days, or when (Behring. Marburg. 
administered to cats or dogs for 180 days in doses Germany) 
CD" leu-M3 1:500 Monocytes. macrophages up to 60 mg/kg.14 The extract does not alter neuro- (Becton Dickinson. San 
muscular transmission either in vitro or in vitro.13 Jose. CA) 
In this study one batch ofTP1 was used through- CD3 leu·4 1:60 Immature and malure 
out. Placebo consisted of 6 mg mannitol in 2 mL functional T-cells (Becton 
saline. DIckinson) 
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chosen fields of malignant epithelial fields were 
analyzed in one or two (depending on the amount 
of tumor tissue available) representative sections 
oCthe tumor (no necrosis, clearly recognizable rna· 
lignant squamous cell tissue). For each such field J 
the area covered by lymphoid cells positive for 
the specific marker was measured via quantitative 
morphometric analysis by Vidss RT system, which 
is based on color differences in the section (dark 
areas being marker-positive), The afea covered by 
marker-positive cells was calculated as a percent-
age ofthe total stromal or epithelial afea analyzed. 
Subsequently, a mean was calculated for each tu-
mor and designated the "relative surface area of 
infiltration." If a relative surface area of infiltra-
tion was less than 0.5%, it was stated as such and 
no exact figure was given. If statistical analysis 
had to be performed in such a case, 0.4% was taken 
as the figure. 
The isolation of blood monocytes and the polar. 
ization assay have previously been described.9•lo 
The latter assay is a rapid method to reflect mono-
cyte chemotaxisY In brief, heparinized blood 
(from patients and healthy controls) was used for 
the enrichment of fresh monocytes. After Ficoll· 
Isopaque, and subsequently Percoll density gradi. 
ent centrifugation, we obtained 60-80% mono· 
cytes as determined by enzymatic nonspecific 
esterase positive (NSE+) staining. These mono-
cytes were tested in the monocyte polarization 
assay by exposing them to a chemoaUractant 
00 nM tMLP) for 15 minutes at 37'C, then arrest-
ing this incubation with 10% formaldehyde. A 
monocyte was microscopically scored upolarized" 
if any of the following features occured: (8) elon· 
gated or triangular shape, (b) broadened Iamelli-
podia, or (c) membrane ruffling. The outcomes 
were calculated as follows: % total cells polarizedl 
% NSE positive cells x 100%. 
Both the cluster assay and preparation ofDCs 
from blood monocytes were performed according 
the methods described by Kabel et a1. 11i In brief, 
rnonocytes were incubated with 14.6% (w/v) metri-
zamide for 30 minutes at 37"C/5% CO2, followed 
by thorough washing. After a 16-hour culture pe· 
riod under nonadherent conditions, this method 
yielded 40-80% DCs.IS These blood monocyte-
derived DCs were allowed to cluster with alloge· 
neic T-Iymphocytes (from healthy controls) for 4 
hour. at 37'C/5% CO, in 250 ILL flat-bottomed 
wells. The number of clusters (aggregates of 4-26 
cells) were counted and expressed per six micro-
scopic fields (inverted microscope, magnification 
x 200). 
Heparinized peripheral blood samples were ob· 
tained from subjects and analyzed the same day. 
Analyses were performed using a FAC scan flow 
cytometer (Becton Dickinson, San Jose, CAl. 
Whole blood was incubated with optimally titrated 
fluorescein isothiocyanate (FITC)-conjugated 
anti-CD3 antibody (Leu·4 FITC, Becton Dickin· 
son) for immunofluorescence staining. As a rule, 
irrelevant IgG2 FITC-conjugated McAbs were 
used as negative controls. Before flow cytometric 
analysis, red blood cells were lysed using F ACS 
lysing solution (Becton Dickinson). The whole 
blood forward and side scatter patterns, and the 
percentages of granulocytes, monocytes and lym-
phocytes (Leucogate) were determined. Data anal-
ysis was performed on the lymphocyte population 
thus defined. This lymphocyte population repre-
sented at least 95% of the total number oflympho-
cytes and contained less than 3% monocytes. 
White blood cell counts were perfonned with a 
Coulter counter model ZM (Coulter Electronics, 
Hialeah, FL). Percentages as well as absolute 
'numbers of the CD3+ lymphocytes were deter· 
mined. 
Sera for immunologic evaluation were collected 
a few hours before surgery, and Sera of healthy 
hospital staff members served as controls during 
the tests. Sera were collected from the patients 
and healthy controls by venipuncture and diluted 
1:1 in saline. These dilutions were subjected to 
ultrafiltration through Amicon CD25 Centriflo 
cones (Amicon) for 15 minutes at 800g (molecu· 
lar mass "cut-off point" 25 kD). The residues 
were resuspended and stored at -20"C until fur· 
ther use. 
Statistical analysis was perfonned using 
the nonparametric, unpaired Mann·Witney test 
Onstat computer program); p < .05 was taken 
~is the level of significance. 
RESULTS 
Tumors of 18 patients who had received TPI treat· 
ment (4 patients received 0.5 mglkg, 6 patients 
received 1.0 rng/kg, 8 patients received 2.0 mglkg 
body weight) and 16 patients who had not received 
TPI treatment (4 patients received placebo, 12 
patients were left untreated preoperatively) were 
analyzed for stromal and epithelial macrophage! 
monocyte, DC, and T-cell infiltration. 
With regard to CD68+ macrophage infiltra-
tion, CD14+ monocyte infiltration, and CDla+ 
and L25+ DC infiltration, there were no statisti· 
cally significant differences between any of the 
groups studied: Table 3 shows mean relative sur· 
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Table 3. Relative surface area of macrophage, monocyte and dendritic ceUlnfiltratlon In TP1-trealed 
and noo-TP1-trealed HNSCC patlents. 
TP1·trealed patients Non-TP1-treated patients 
Stromal infiltration (%) Epithetiallnfiltration (%) S\romallnfiltratlon (%) EpitheliallnfiUratJon (%) 
C068' macrophages 8.8 2.9 8.6 2.5 
CD 14' monocytes 
(n= 1780=2.4) 
8.5 
(n = 17, SO := 2.6) 
1.7 
(n = 13, SO = 2.4) 
7.2 
(n = 13, SO = 1.9) 
2.0 
COla' dendritic cells 
(n = 17, SO = 2.4) 
<0.5 
(n = 17, SO = 1.1) 
1.0 
(n = 13, SO = 2.3) 
<0.5 
(n ~ 13. SO ~ 1.1) 
1.8 
(n:= 17) 
l2S' dendritic cells 2.8 
(n = 17, SO = 0.9) 
0.7 
(n = 15) 
3.0 
(n = 14, SD = 1.6) 
0.5 
(n = 15, SO = 1.0) (n = 15, SO = 0.5) (n = 12, SO = 1.4) (n = 12, SO = 0.3) 
n = Number of !UfTIOfS studied. 
face areas of infiltration for each of these cells in 
tumor stroma and malignant epithelium. In this 
table patients are divided into two groups for rea-
sons of simplicity only (a TPl-treated and a non-
TPl-treated group). 
However, T-cell infiltration into the stroma of 
tumors was much denser in patients treated with 
TPI than in patients who had not received TPI 
(Figure la and Ib, Table 4): the mean relative 
surface area ofTPl-treatedpatientswasl0.7%(n 
~ 18, SD ~ 4.0) and 4.8% (II ~ 16, SD ~ 1.54) for 
the non-TPl-treated patients. This difference is 
highly statistically significant (p < .0001). With 
regard to the various subgroups: Mean stromal 
CD3+ cell infiltration for the 0.5 mg/kg, 1.0 mg! 
kg, and 2.0 mglkg subgroups were 10.3% (n = 4, 
SD ~ 2.25), 13.0% (n ~ 6, SD ~ 2.03), and 9.11% 
(n = 8, SD = 5.10), respectively, each separately 
being significantly higher than the non-TP1-
treated group (p < .001, p < .0005, p < .05). In-
traepithelial infiltration of CD3+ T-cells was 
much less than stromal infiltration, but also ap-
peared to be denser in the tumors ofTPl-treated 
patients as compared with the tumors of non-
TPl-treated patients 0.2% versus < 0.5%). How-
ever, this difference did not reach statistical sig-
nificance. 
Correlations were studied between the pres-
ence in the tumor of the various infiltrating cells 
and the outcome of the polarization assay on pe-
ripheral blood monocytes, the cluster capability of 
DCs isolated from the peripheral blood, and the 
numbers of blood CD3+ T-cells. Positive signifi-
cant correlations could not be established between 
the presence in the tumor ofCD68+ macrophages, 
CDI4+ monocytes, or CDla+ and L25+ DC8 and 
either the monocyte polarizing or DC clustering 
capability. However, there was a significant posi-
tive correlation between the number ofT-cells in-
filtrating into the stromal compartment of the tu-
FIGURE 1. (A) CD3+ T-cell InfillfaUon In an orophalYngeal carcInoma (T2N2MO) of a TP1-treated patient Nole the dense InfiltraUon 
of T-cells Into the stromal Ussue (relallve surface area of InfitlralJon, 18.3%). (8) CD3+ T-cellinfiflral!oo In an oropharyngeal carcinoma 
(T3NOMO) of a non-TP1-tfeated patient. The InfillraUon of T-ceHs Is slgnlflcanlly loWer than In tumors of TP1-trealed pallents (relative 
surface area of Infiltrallon, 4.1Y',{,). 
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Table 4. Mean relative surface area of C03t T-celllnfi!\ra\lon In tumors 01 TPHreated 
and ooo-TP1·lrealed patients. 
Stromal I-celt Infiltration (%) Epithelial T-celllnlHlrallon (%) 
Untreated (group 0) 5.0 <0.5 
Placebo (group I) 
(n = 12, SO = 1.62) 
4.1 
en'" 12) 
<0.5 
(n ~ 4) 
<0.5 Non-TPI-ireated (group 0 + I) 
(n = 4, SO = 0.8) 
4.8 
(n = 16, SO = 1.54) (n = 16} 
0.5 mg/kg TPI (group II) 
1.0 mg/k9 TPI (group III) 
2.0 mgJkg (group IV) 
TPI treated lotal (groups II. III, IV) 
10.3 (n = 4, SO = 2.25, P < .001) 
13.0 (n = 6, SD = 2.03, P < .0005) 
9.11 (n= 8, SO = 5.10, p< .OS) 
10.7 (n = 18, SD = 4.0, P < .OOOl) 
2.0 (n = 4, SO ~ 2.25) 
0.9 (n = 6, SO = 0.43) 
1.7 (n = 8,.SO = 1.80) 
1.5 (n = 18, SO'" 1.3) 
n = Number of \tIfOOfS studied; p-vaJue Is given in regard 10 !he noo-TP1·tleated gloup. 
mor (these T-cells are found clustering around 
infiltrated DCs, as illustrated in Figure 2 and ear-
lier reported in detail11) and the numberofc1usters 
found in the cluster assay using peripheral blood 
DCs (r = .4, n = 25,p = .05). No correlation existed 
between CD3+ T-cell infiltration into the tumor 
and CD3+ T-cell numbers in peripheral bloodJ nor 
between tumor T-cell infiltration and monocyte 
polarization. 
DI8CU8SION 
This study shows that HNSCC samples from pa-
tients treated with TPI had a denser infiltration 
ofT-cells into the stromal compartment of the tu-
mors than from patients who were untreated or 
those who received a placebo. Our methodology 
allows comparison only between treatment groups 
(and not individual patients). because it is based 
on the analysis of only 1 or 2 sections of each 
tumor (there may be significant differences within 
F1GUAE 2. Double staInIng of HNSCC for CD3+ T·ceUs (3.3'· 
deamlnobenzldine·telra·HCl, brown·colored cells) and l25+ 
dendritic cells (fast blue, blue·colored cells) formIng a cell cluster. 
tumors); nevertheless our data give a strong indi-
cation that TPI enhances T-cell infiltration into 
HNSCC. Effect ofTPl treatment was not seen on 
the pattern and distribution of infiltrating mono-
cytes, macrophages, or DCs, the infiltration pat-
terns and distributions within the tumor being 
similar to earlier reports.n.,S The enhancing effect 
on T-cell infiltration ofTPl occurred in all three 
dosages used. In our earlier report we showed that 
1.0 mg TPllkg and 2.0 mg TP11kg body weight 
were the most effective dosages for the restoration 
of the defective chemotaxis of blood monocytes in 
HNSCC patients,'·10 although 0.5 mg TP11kg body 
weight was most effective in restoring the defec-
tive DC clustering capability. In the present study 
1.0 mglkg TPI had the greatest eifect, but 0.5 mg 
and 2.0 mg TPlIkg were also effective. 
A dense infiltration ofDCs has been related to a 
better prognosis in laryngeal,19 nasopharyngeal,2Q 
and esophageal carcinoma,21 as weH as in uterine 
cervical and gastric carcinoma7Mt Dendritic cells 
have an important immune function by presenting 
-(tumor-associated) antigens to T-cells. In this pro-
cess they fonn clusters with the T-cells. Regarding 
this function it seems of no surprise that a correla-
tion between numbers of tumor-infiltrating DCs 
cells and T -cells has been described in the past.25 
In our study an enhancement ofT-cell infiltration 
into the tumor afterTPl treatment was notaccom-
panied by a denser DCUnfiltration. We did, how-
ever, establish a positive correlation between T-
cell tumor infiltration and the capability of blood 
DCs to fonn cellular clusters with T-cells, thereby 
suggesting that not only numerical infiltration of 
DCs, as found in earlier studies, but also the func-
tional status of the ceJls is of importance in cell-
mediated tumor-related immunologic events. This 
is very much in line with the earlier-described 
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improvement of De clustering capability afterTPl 
treatment,IO and the currently reported enhance-
ment of T-cell infiltration into the tumors of the 
same TPl-treated patients. The mechanisms by 
which DC functions Bfe influenced are not under-
stood. First, DCs fonn a heterogenous ceU popula-
tion with probably more than one precursor ceU. 
For monocyte-derived DCs it has been shown that 
TPlstimulates the maturation orDes from mono-
CyteS.9 Safer et al2t'i demonstrated that the thymic 
factor Thymosin Beta 4 is important in the poly-
merization of actin in highly motile cells such 8S 
blood platelets and neutrophils. DCs are also 
highly motile cells, containing abundant actin fil-
aments 8S contractile proteins.27 Similar to the 
platelets and neutrophils, the actin filaments of 
DCs may be influenced by thymic hormones such 
as TPl. Because the clustering process of DCs is 
an active process that is highly dependent on the 
motility of the cells, it is possible that TPI stimu· 
Jates DC clustering by stimulation of polymeriza-
tionldepolimerization of the actin filaments. 
Reports concerning the clinical relevance of a 
dense T-cell infiltration into tumor areas are in-
conclusive so far. A dense stromal T-cell.infiltra-
tion has been correlated to a betwr prognosis in 
HNSCC patients23•29 as well as in stage I malignant 
melanoma. 3() However, OaH031 found no correlation 
between T-cell infiltration and prognosis in naso-
pharyngeal carcinoma, whereas in papillary carci· 
noma of the thyroid and renal cell carcinoma an 
enhanced T-cell infiltration has been associated 
with an unfavorable prognosis.32 Therefore, the 
clinical relevance of the findings of our present 
study is as yet unclear. 
Controversy also exists about tumoricidal ca-
pacity of macrophages,11 but in nasopharyngeal 
carcinoma intratumoral infiltration ofmonocytes/ 
macrophages has been related to a favorable prog-
nosi8.25,31 Patients with HNSCC are often charac-
terized by a defective chemotactic capability of 
blood monocytes,4,1 which has been correlated to a 
decreased infiltration of acid phosphatase-positive 
macrophages into the tumor area. 4 We previously 
reported a restoration of monocyte chemotactic 
function in patients treated with TPl.loThis study 
shows that TPI treatment did not result in a sig-
nificantly denser infiltration of monocyteslmacro-
phages into the tumor, nor did a correlation exist 
between the presence ofCD68+ macrophages and 
CD14+ monocytes in the tumor and the monocyte 
chemotactic ability as measured with the mono-
cyte polarization assay. It seems inevitable to con-
clude from this study that no direct relationship 
appears to exist between monocyte chemotactic 
functions in the peripheral blood on the day of 
surgery and the number of monocytes and 
monocyte-derived cells present in the tumor. 
In conclusion, this study confirms our earlier 
observations9,lo that TPI treatment with a thymic 
hormone preparation results in a discrete stimula-
tion of the ceB-mediated immune system in 
HNSCC patients, In addition to the earlier· 
reported restoration of impaired monocyte motil-
ity and DC clustering capability, TPl treatment 
also resulted in a highly significant denser T-cell 
infiJtration into the tumor. It cannot be concluded 
from the present study (in principle, a dose-finding 
study) If the described stimulation of the immune 
system by TPI results in a better clinical outcome. 
A preliminary follo;av-up of our patient population 
suggests effects o('rPl-treatment neither on re-
currence of the disease nor on morbidity. Larger 
proElpective studies designed to address this ques-
tion are necessary. 
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The effects of thymostimulin on immunological function in patients with head 
and neck cancer 
Patients with head and neck carcinoma show deficits of cellular immunity, prob\lbly due to low molecular 
mass factors (LMMFs) released by the tumour. Thymostimulin (TPI) restores 'he defective monocyte 
chemotaxis and dendritic cell clustering capability in the presence of the tumour when adminislered pre-
operatively. Inlhe present study we investigated these immune parameters in 39 patients treated with TPI 
for 10 da)'s pre- and 6 months post-operati\'e1y and in 22 patients who were not treated with TPI for 6 
months after operation. Removal of the tumour in non-TPI-Irealed patients also resulted in a restoration 
of monocyte and dendritic cell fUnctions, while TPI treatment gave no additional effect. LMMF levels in 
the blood of both TPI-treated and 1I0n-TPI-treated patients remained elevated evcn after removal of the 
tumour, and it is therefore concluded that it is unlikely that depression of cellular immunity is a direct 
effect of these LMMFS. 
Keywords hcad alld neck carcinoma immul/otherapy thymostlmlllht lIuJIloq/es dendritic 
cells plSE 
Introduction 
Patients with head and neck squamous cell carcinoma are 
immunologically compromised and show deficits in their cell-
mediated immune system, including defective skin tests on 
specific and non-specific stimuli, defecti\'e chemotaxis of 
monocytes and defective interaction of dendritic cells with 
lymphocytes. I-a Dendritic cells are important immune acces-
~orycells that act by presenting antigens to T cells. The defects 
in cellular immunity are thought to contribute to tumour 
growth, since the immune system is important in host defence 
Correspondence: A.l.M. Balm, Department ofOtolaryngologyJHead 
and Neck Surgery. The Netherlands Cancer Institute. Plesrnanlaan 
121. 106 6CX Amsterdam. The Netherlands. 
against malignancies. With regard to the origin oflhedefective 
function of monocytes, dendritic cells and T cells low molec-
ular mass factors (LMMF) produced by the tumours may be 
important. Previously we demonstrated that these factors. 
which show a structural homolog), with the retroviral protein 
plSE and with IFN-alpha 2b.9.tn depress. not onl)' T cell and 
N K cell function. but the ability of monocyles to cilange shape 
(polarization), the laller function being related to monocyte 
migratory and chemotactic capabilities.s The defective capa-
bility of dendritic cells to form clusters with I)'mphocytes has 
also been ascribed to the suppressive effect of the tumour-
derived LMMFs.8 •II •n A direct correlation between serum 
levels of LMMFs in palients with head and neck cancer and 
defective monocyte polarization or dendritic cell-lymphocyte 
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clustering could not, however, be demonstrated in an earlier 
report. 1l 
Thymmtimulin (TPI) is lin irnmtlllOslimlllating drug pre-
pared from calf thymus extracts. When TPI was added to the 
monocytes or dendritic cells of patients with head and neck 
cancer ill rilm, it resulted in the restoration of derective mono-
cyte polarization and dendritic cell c1ustering.s II/viM, also a 
restoration of cell-mediated immunity was seen at the time of 
surgical removal of the tumour when the drug had been given 
pre-operatively for 10 days. It was also remarkable that the 
tUIllOurS of these patients treated preoperatively with TPI 
showed a denser infiltration ofCD3+ T-Iymphocytes (inter-
mingled with dendritic cells) when compared with tumours of 
non-TP I-treated patients. f4 
This study investigates the effect1'i of thymostimulin on 
monocyte function, dendritic cell function and numbers or-I'· 
lymphocytes, T-Iymphocyle subsets and NK-cells in a period 
of up to 180 days after surgical removal of the tumour. In a 
randomized trial patients were, in addition to conventional 
therapy (surgery or surgery and radiotherapy), treated with 
one of three regime1'i ofTPI treatment (O.S mg/kg; 1.0 mg/kg; 
2.0 mg/kg) or a placebo. from 10 days prior to surgical 
removal of the tumour to 6 months post-operati\·ely. A group 
of patients not immunologically treated was also included. 
l\·tonocyte polarization, the capability of the monocyte-
derived dendritic cells to cluster with allogeneic lymphocytes. 
serum plSE-like LMMF levels and numbers of blood lym-
phocytes and lymphocyte subsets were monitored for the 
entire period of treatment. Allhough the study was not 
designed to evaluate the prognostic relevance ofthe treatment. 
outcome in terms of recurrence will nevertheless be 
considered, since the majority of patients have now been fol-
lowed-up for a period ranging frolll 30 months to S yr. 
Material and methods 
PATIENTS 
Forty-one patients with a squamous cell carcinoma of the 
oral cavity. oropharynx. hypopharynx and larynx agreed to 
participate in a multiccntre trial. Inclusion criteria have been 
listed before in detail;B most important. patients with co· 
existent disease were excluded. The patients were randomly 
entered into one of the four following groups: patients receiv-
ing placebo treatmcnt (group A); patients receiving 0.5 mg/kg 
TPI (group 8); patients receiving 1.0 mg/kg TPI (group C); 
and patients receiving 2.0 mg/kg TPI (group 0). This dosage 
scheme was chosen since 1.0 mgjkg TPI has been reported to 
be effective in several immunodeficiency disorders. lS . f1 In the 
placebo group olle patient developed all unexplained throm· 
bosis and one patient developed pulmonary complications 
post-operatively. Both patients were excluded from further 
study, leaving 39 patients for evaluation. Treatment consisted 
of 10 dnily pre·operative intramuscular injections, and 21 
daily post·operative injections, after which treatment was con-
Hnued for 21 weeks twice weekly. 
Additionally. 22 patient1'i operatcd upon in the same period 
and who did not receive TPI or placebo were studied as an 
additional control group (group E). Patients were entered in 
group E if they met the inclusion criteria, but declined to 
participate in the trial (they did consent to serve as controls). 
In this group, four patients consented to pre·operative lab-
oratory tcsts only, one patient WlIS lost to follow·up and in two 
patients n macroscopical incomplete resection was performed; 
the post·operative dala on these three patients were therefore 
cxeluded from evaluation (leaving 19 patients for evaluation 
in group E). 
TNM classification ranged from TlNI to T4N2. Local-
ization and classification were evenly distributed over all 
groups of patients entered inlo the Irial, as well as patients in 
group E. Primary treatment consisted of surgery alone (15 
patients) or surgery followed hy radiotherapy (43 patients). 
Blood was taken hefore starting the TPI injections (day 
-10). on the day of operation (day 0) and on day 21. day 90 
and day I RO po.~t-operatively for the lahoratory tests descrihed 
below. One patient inlhe trial population de\'eloped a second 
primary head and neck carcinoma within the follow-up 
period. post-operati\'e laboratory data were therefore 
excluded from evaluation concerning the prognostic value for 
recurrencc. 
Clinical follo.w-up was until recurrence or for a minimum 
of 30 months up to S yr. 
BOVINE THYMIC F.XTRACT (nIYMOSTIMULlN, TPI) 
Thymostimulin was prepared as a bovine thymic extract using 
the following proccdure. described by Dergesi and Falcheltif~ 
and Falchetti ('/ {fl. fg Calf thymus glands were minced and 
extracted with ammonium acetate. The extract was then 
heated to 7O"'C, filtered. and precipitated with ammonium 
sulphate. The precipitatc was dissolved in water and subjected 
to ultrafiltrution on an Amicon PM-IO membrane. The filtrate 
was desalted on Scphadex G-2S and gel-filtered on Sephadex 
G-SO. Fractions showing characteristic bands at RF 0.22 and 
0.24 on polyacrylamide gcl electrophoresis werc comhined 
and termed 'thymostimulin' (TPI). This extract was next 
lyophilized and its activity expressed as units ofT·cell·roselie 
formation per milligram of protein. No endotoxin was COIl-
tained in this extract, as tested in doses up to 100 mg/kg when 
administered to mice for 21 days or rats for 31 days, or when 
given to cats or dogs for 180 days in doses up to SO mg/kg.f9 
Additionally, the extract failed to alter neuromuscular trans· 
mission il/ "itrn or ill t·it·O.f~. 
ISOLATION OF RLOOD MONOCYTES AND MONOCYTE 
POLARIZATION ASSA Y 
The isolation of blood monocytes and the polarization assay 
have previously been described in detail.~·fJ The latter assay 
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correlates 10 monocyte migration and chemotaxis.-' In hrief. 
heparinized hlond (from patients and healthy controls) was 
used for the enrichment of fresh monocytes. After FicoU-
Isopaque. and subsequently Pereol! density gradient cell-
trifugatioll, we obtained 60-80% monocyte.'> as determined 
by enzymatic non-specific esterase positive (NSE+) staining. 
These monocytes were tested in the mOllocyte polariz<ltion 
assay by exposing them 10 a chemo-attractant (10 11M fMLP) 
for 15 min at 3TC, and arresting this incubation with 10% 
formaldehyde. A monocyte was microscopically scored 
'polarized' if any of Ihe following features occurred: (a) elon-
gated or tl'iangul:lf shape; (b) broadened lamcllipodia: and (e) 
memhrane ruming. The outcome was calculated as follows: 
% total cells polarized/% NSE+celis x 100%. 
~fONO(,YTF.-I)P.RI\,IlU DENDRITIC CP.I.l.S ANlJ THEIR 
CLUSTERING CAPAfllUTY 
Dendritic cells were maturated from blood monocytes and 
their cluster behaviour wilh lymphocytes was assayed accord-
ing to the methods described by Kabel el ai. indetai!.l0 In brief, 
monocytes were incubated with 14.5% (wI\') metrizamide for 
30 min at 3TC15% CO2• and thoroughly washed. After a 16-
h culture period. under non-adherent conditions. this method 
yielded 40-80% dendritic cells.21 
These monocyte derived dendritic cells were allowed to 
cluster with allogeneic T-Iymphocytes (from healthy controls) 
for 4 h at 3TC15% CO2 in 250 pi nat-bottomed wells. The 
number of clusters (aggregates of 4-25 cells) were counted 
and expressed per six microscopic fields (inverted microscope, 
200 x magnification). 
NUMnER OF BLOUlJ LYMPHOCYTES AND l.YMPHOCYTE 
SUBSIlTS 
Details (In the technique can be found elsewhere.ll Hep-
arinized peripheml hlood samples from patients anu controls 
were obtained ami analysed. Whole blood was incubated for 
the detection of surface markers by the use of optimally 
titrated monoclonal antibodies. Isotype identical irrelevant 
monoclonal antibodies. conjugated with either FITC or PE, 
were used as negalh'e controls. We used the markers CD3 
(Leu-4 FITC. Becton Dickinson), CD4 (Leu-3 PE or Leu-
3 FITC. Becton Dickinson) and CD8 (LEU-2 PE, Becton 
Dickinson) to label T cells. For natural killer (NK) ceils, the 
marker CDI67 (Leu-lie PE, Becton Dickinson) was used. 
CDI4 (r..·tY4 PE, Coulter Clone) was used to determine the 
percentage of granulocytes. monocytes, and lymphocytes. 
Data analyses were performed on the lymphocyte population 
thus defined. This popUlation represents at least 95% of the 
total number of lymphocytes and contained less than 3% 
l'ontamination with monocytes. White blood cell cOllnts were 
performed with a Coulter counter. The surface membrane 
lahellinp.s werc IllC<lSUfl't! anti nn<llpctl u~jng a FACScan 1I0w 
cytometer and FACScan research software. 
DETERMINATION OF pI5E-l.IKE LMMFS IN SERA 
Sera were collected prior to the first TPI injection and 1-2 h 
berore surgery. Sera of healthy hospital staff members served 
as controls. Sera were collected from the patients and healthy 
controls by venipuncture and diluted I: I ill saline. These 
dilutions were subjected to ultrafiltration through Amicon 
CD25 Centrino cones for 15 min at SOO g (molecular weight 
'cut off point' 25 kD). The residues were resuspended and 
stored at - 20"C until further lise. 
The capability of the serum fractions to inhibit fMLP-
induced polarization of healthy donor monocytes (e1utriator 
purified) was determined by incuhating the monocytes 
(I x 106/ml) for 15 min at 37T, either wilh fMLP alone or 
with fMLP in combination with a serum fraction (final 
dilution I: 60). The percentage of inhibition was calculated as 
follows: 
i = (I-(Ff-fo/Mf-fo» x 100% 
Ff = % 1JI0nocytes polarized after incub;ltion with llifLP and 
LMMF, Mf= % l11onocytes polarized after incubation with 
fMLP alone, fo = % spontaneously polarized monocytes. 
Addition ofsenllll fractions to non-fMLP stimulated donor 
monocytes did not affect the spontaneous polarization. 
To validate the rl5E-like character of LMMF adsorption. 
experiments were carried out by neutralizing serum fractions 
at 4~C for 16 h before testing the effects on monocyte polar-
ization by using a combination of two riSE specific mono-
donal antibodies (4F5 and 19F8 as anti-pl5E isolypes IgG2a 
and IgG2b). The final mAb dilution was I: 200 and finallgG 
concentration 50 JIg/m!. Following neutralization, Amicon 
ultrafiltration' was performed to remove complexes. The 
adsorption/neutralizing procedure was carried out twice. 
Irrelevant anti-hulllun .g.02a and IgU2b were used as 
controls. 
Statistical analysis 
Statistical analysis was performed using the Wilcoxon 
matched pairs signed ranks lest and the Kruskal Wallis test. 
Results 
MONOCYTE POl.ARIZATION 
Table 1 shows the percentages ofmonocyles capable ofpolar-
izing on exposure to the chemo-attractant fMLP for the four 
groups of patients entered into the trial. as well as for the 
group of conventionally treated patients (group E). There 
was a significant improvement in monocyte polarization from 
17.6% 1030.9% after JO days of pre-operative treatment with 
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Table I. Monocyte polarization (in percentages) 
D,y Group A Group B Group C Group D Group E 
-10 24 20.9 17.6* 17.St 
(1I=9jSO 14) (/I = 10; so 7.0) (n = 13j so 8.2) (/I = 9; so 8.2) 
0 25.7 13 30.9* 32j 19.5t 
(operation) (11= 9; SD 8.3) (11= lO;sD 10.1) (/I = 13; SD 13.8) (/I = 9; Sf) 15.7) (n = 22; so 7.9) 
21 32.1 24.9 32.2 23.7 25.4 
(11= 7; so 14.7) (/I = 8; so 7.4) (/I = IJ;SD 11.9) (1/ = 9; so 10.6) (/I = 16; so 9.7) 
90 35.1 27.9 30.5 28.8 JO.7t 
(11 = 7;so 12.0) (II = 10: so Il.ll (II = 13; so 12.0) (/I = 8; SI) to.7) (n = II; Sf) 7.3) 
ISO 24 30,6 27.9 29.3 18.3 
(11= 5;50 12.2) (/I = 10; SD 9.5) (/I = 12; SI) 7.9) (II = 8; SIJ 12.7) (/I = 10; so 5.3) 
Group A = placebo; group B = 0.5 mg/kg TPI; group C = 1.0 mg/kg TPI; group D = 2.0 mg/kg TPI; group E = con\'entionally treated . 
• p < 0.05 
tr < 0.05 
fP < 0.05 
1.0 mg/kg TPI and from 17.8% to 32.0% for 2.0 mg/kg TPI 
(as has been reported before).1l Such improvements were not 
seen in the placebo and 0.5 mg/kg TPI groups. 
With regard to the long-term effects ofTPI, it is essential 
to note that the group of conventionally trealed patients 
(group E) showed a significant (P < 0.05, Wilcoxon) improve-
ment in monocyte polarization after operation: a \'alue of 
19.5% polarized monocytes on day 0 (day of operation) rose 
to 30.7% on day 90 post-operatively. This restoration of 
monocyte polarization after surgery is a phenomenon 
described befores and the removal of the tumour with its 
suppressive factors is held responsible for this restoration. The 
mean pre-treatment monocyte polarization of the placebo 
group (24%) was only relatively mildly disturbed (Table I); 
therefore the improvement to 35.1 % after surgery was not 
slatisticallysigniftcant. TPI treatment (groups B, C, D) had no 
further stimulating effects on the already restored monocyte 
polarization after surgical removal of the tumour; at day 90 
there was therefore no difference between the groups. 
At the end of the treatment period (day 180) the Kruskul 
Wallis test showed a difference (P < 0.05) between groups, 
suggesting a renewed disturbance of monocyte polarization in 
the non-TPI treated patients (Table I). The number of pa-
tients at day 180 in the various treatment groups was too 
small to evaluate. 
DENDRITI(' CELL CLUSTJlRING 
Table 2 shows the mean values of the dendritic cell cluster 
assay for the five treatment groups. The pattern is similar to 
the outcome of the monocyte polarization assay. A significant 
preoperative improvcment (P < 0.05) from 86 to 121 was 
found for the 0.5 mg/kg group.!) For both the 1.0 mg/kg 
and 2.0 mgjkg group the pre-operative improvement was not 
statistically significant. At day 90 post-operatively, a sig-
nificant impro\'ement (P < 0.05) of the dendritic cell cllIS-
tering capability compared to the pre-operative value (day 0) 
was again seen for the untreated group (Table 2) and the 
phenomenon was now also evident in the placebo-treated 
group. Such improvements were also recorded for the 1.0 
mg/kg and the 2.0 mg/kg group; however. in the lalier this 
did not reach statistical significance. In the 0.5 Illg/kg group, 
pre-operative improved values did not rise further from day 
o to day 90 post-operatively. 
AI day 180 after operation 110 statistical significant differ-
ences for the dendritic cell cluster a~say were found between 
any of the five grour.s. 
P!5B-LlKI\ LMMFS 
Table 3 shows the mean levels of plSE-like U.U.fFs in the 
serum ofthe five treatment groups. In all groups pre-operative 
values of serllm LMl-.'IFs (measured by percentage inhibition 
of polarization of healthy donor monocytes) were con-
siderably higher than the mean percentage inhibition of donor 
monocytes by pl5E-like LMMFs in the group of he:llthy 
controls. TPI treatment had no effects 011 these levels, and on 
the day of operation similarly elevated mean serum levels of 
LMMFs were found in groups A. Band C. as wcll as in groups 
D and E. The mean LMMF serum-levels did not drop post~ 
operatively in any of the groups and rcnHlined elevated ror 
6 months post-operatively. If patients were divided into a 
recurrence and a non-recurrence group (for details see further) 
as is shown in Figure I. pre-operath'c pl5E-like lMMf levels 
were similar in hoth groups and we did nol see the post-
operath'edecline in LMM F levels in the nOli-recurrence group 
as was reported in an earlier studyY 
LYMPHOCyTES AND LYMPIiOCYTJl SUnSJlTS 
The values of the number of blood CD3+ T cells, CD4+ 
and CDS+ lymphocyte stlb~ets. CDI6+ NK cells and CDI4+ 
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Table 2. Dendriticcell clustering 
D,y OroupA Group B 
-10 120 86t 
(1/ = 9; so 40.11) (1/ = 9; SI) 37.0) 
0 III' 121t 
(operation) (11=6;5027.7) (II = 9; so 38.2) 
21 122 125 
(II = 5; so 15.5) (/I = 8; Sf) 36.3) 
9Q 139' 128 
(n = 6; so 21.2) (1/ = 8; so )4.1) 
180 JI7 
'" (1/ = 4; so 40.6) (II = 9; so 26.2) 
Groupe 
100 
(n = 12; Sll 34.2) 
1I7t 
(/I = II; so 23.0) 
126 
(1/ = 10; so 18.5) 
144t 
(1/ = 13; so 32.5) 
I2J 
(1/ = II; so 18.6) 
Group D 
98 
(/I = 9; Sf) 30.5) 
113 
(/I = 9; sn 23.0) 
IOJ 
(11= 9; su 30.1) 
13' 
(n = 7; so 50.3) 
140 
(1/ = 8; so 34.5) 
Group E 
1112§ 
(II = 20; w 23.5) 
'" (/1 = 13; so 29.0) 
142§ 
(11=9;5021.7) 
'" (/I = 8; so 20.]) 
Group A = placebo; gcoup B = 0.5 mg/kg TPI: group C = 1.0 mg/kg TPI; group D = 2.0 mg/kg TPI; gf(1UP E = comclltiomllly treated. 
·P<O.05 
tP < 0.05 
fP < 0.05 
§P < 0.05 
Table J. rlSE·like LMMF le\'el.~ (in percentage, fMLP-induced donor monoq'le polluization inhibition) 
Oay Group A Group 0 Groupe GroupO Group E 
-10 24 20 II II 
(1/ = 7;so 14) (II = 10; so 15) (1/ = 10; so 15) (11=8;51)9) 
0 24 18 20 19 16 
(opcralion) (1I=7;5UI8) (1/ = 10; 511 10) (II = 10;51116) (1I=8:~fllJ) (/I =8:~h 19) 
11 26 II 24 II 11 
(1/ = 5; so 22) (1/ = 8;so 13) (,,=8;5018) (,,=8;suI9) (II = 7;5f) 14) 
9Q 16 19 
" 
18 II 
(1/ = 5;s09) (1/ = 10; Sll II) (1/ = 10: SIl 9) (,,=6;sn 15) (/I = 5; sn 19) 
180 II 16 11 lJ 18 
(1/ = 5;51) 14) (/I = 8;51) 15) (1/ = 8;sl) 18) (1/ = 7; ~fl 17) (/I '" 5;~h 15) 
Group A = placebo; group B = 0.5 mykg TPI; group C = 1.0 mg/kg TPI; group 0 = 2.0 mgjkg TPI; group E = con\'enlionally treated. 
mOllocyles are not separately !'ihown. No statistically sig-
nificant difference in the numbers of any of these cells was 
found between patienls and healthy controls, nor hctween 
different treatment groups at any time. Thus, neither f(lf TPI 
treatment (in the pre5ence or absence of the tumour), nor for 
operation, could an effect on the number of these cells be 
demonstrated. 
RECURRENCES 
The number ofpatient~ in this study is too small 10 do a valid 
statistical analysis on the effect ofTPI treatment and immune 
performance 011 recurrence rate~ (lhe study wa~ not designed 
for this purpose). However, we felt it important to evaluate 
trends for the design of possible further studies. 
In the placebo group 5/7 (71%) of the patients had a recur-
rence of disease within 30 months, whereas in the con-
ventionally treated group only 4/19 (21%) had a recurrence, 
giving in total a recurrence rate of 9/26 (34.6%) in the non-
immunologically treated patients (however, the range !;Jelween 
the two groups is not acceptable). With regard to the TPI 
treated groups, 2 of 10 (2f1%) patients in group n (0.5 mg/kg), 
7/13 (54%) in group C (1.0 mi/kg). alld 3/9 (33%) ill group 
D (2.0 mg/kg) developed recurrences. Hence in total 12/32 
(37.5%) TPI treated patients developed a recurrence. and 
this is not different from the non-immunologically treated 
patients. 
For the purpose of further analysis, patients were divided 
in two groups: patients who developed a recurrence and those 
who did not. Localization of tUIllOur and T stage were similar 
in both groups; the recurrence group had slightly more neck 
node involvement. Patients who rece1\'ed TPI were equally 
distributed over both groups: 55% versus 51 % (of the patienls 
with a recurrence, :\7.5% receivcd TPI in any uf thc three 
regimes and 34.6% did 1101 receive TPI). Wecould not demoll-
strate a correlation between the presence of dcfective Jllono-
cyte polarization (dennel! as a value of < 18.4%)1.' pre-opcr-
atively or at any time post-operatively and the development 
of a recurrence, neither was there ~uch a correlation hetween 
defective dendritic cell-lymphocyte clustering <defined as a 
value of <92 clusters)!" and recurrence of disease. 
It must be noted, however/lhat of the ollly three patients 
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FigurE' I. Serum plSE·like LMMF levels in the group ofpatienls who 
developed a recurrence and the group of patients who did nol develop 
a rccuri-con:", 0 = recurrence; • = non· recurrence. 
who had holh defective monocyte polarization and defective 
dendritic cell·lymphocyte cluster capability at the cnd of the 
treatment period, lwodeveloped a recurrence thereafter. while 
the third patient developed a squamous cell carcinoma of the 
lung. On the other hand, of the patients (1/ = 3) who had fully 
reslored monocyte polarization (defined as a value at the 
upper limit ofnorlllalily; > 30%) and a fully restored dendritic 
cell-lymphocyte clustering (defined as a value at Ihe upper 
limit ornormality; > IJOciuslers) on day 180, none developed 
a recurrence. 
Discussion 
The present :;tudy Hnd an earlier onel) have shown that thYl1lo-
stimulin (TPI) treatment for 10 days prior to surgery, did 
restore to normal defective monocyte polarization and defec-
tive cluster c,lpability of dcndritic cells. We also reported on 
an curlier occasion that tumour infiltration with CD) f T 
cells was much denser in the patients treated with TPI pre-
operatively.u It must be noted. however, that statistically 
significant dilTerences were reached with different TPI do~e,~; 
1.0 mg/kg and 2.0 mg/kg bodyweight were the best doses to 
restore monocyte polarization. while 0.5 mgjkg was best to 
restore the dendritic cell cluster capability. The enhanced T 
cell infiltration of the tumour itself was seen wilh all three 
doses ofTPI. Whether these findings on dose-effects are reat 
or only due to the small numbers of patients studied in each 
group needs further investigation. 
The present data on the long-term effects ofTPI treatment 
(90 and 180 days post-operatively) take our earlier obser-
vations further and confirm that ablative surgery in itself 
resu Its in a restoration of Illonocy te polarization and dendritic 
cell clustering capability.s The study also shows that TPI 
treatment has no further immune stimulating effect in the 
90 days following operation. Hence, TP I does not seem to 
stimulate Illonocytes and dendritic cells directly, but seems 10 
restore them to normal in the pre-operative period when the 
tumour is still present. A rationale for TPI treatment after 
surgical removal of the tumour is hence lacking. It must also 
be noted that neither the presence of the tumour nor treatment 
with TPI had any short or long-term effects on the number 
of T lymphocytes, T lymphocyte subsets, B cells or NK cells 
in the peripheral blood. 
Despite the fact that conclusions concerning clinical effects 
may not be drawn from the present trial, we did not find any 
sign of evidence for an improvement in disease outcome in 
TPI treated patients. If would, however, be incorrect to con-
clude at this stage that TPI is an ineffeclive adjuvant in the 
treatment of head and neck cancer. TPI may turn out to be a 
beneficial adjuvant, especially for selecled patients with a 
clearly disturhcd cellular immune system before operation. 
Further studies could foclis Oil the use of thymic hormone 
treatment under these cirellmsi;lnces. 
We and othersl..l·UI>.IJ_2~_25 have extensively reported the 
defcdive lIlonocyte pol<lri7:1tioll and the related defective 
monocyte chemotactic functions in head and neck cancer, as 
well as on {he defective dendritic cell clustering capability. 
These various defective fUllctions of the cell mediated imlllune 
system were assumed to be caused by an immunosuppressive 
protein produced by the tumour and released into the serum. 
Cianciolol~ was the first to demonstrate that human tumours 
release such low molecular lIlass factors with il/ t'ifro immuno-
suppressivecapabilitiesY These LMMFs were later shown to 
have a strong functional and structural homology with the 
retroviml protein pl5Eand were therefore referred to as p15E-
like I.MMFs, Tmllours alltl sera of patients contain these 
Lf>.'1 M Fs, and they were shown to inhibit monocyte polar-
izatil1Jl ill /'ifni.] The cellular mechanism by which pl5E-like 
LMMFs innuencc monocyte motility is. howcver. not clear. 
Moreover. pl5E-like U.'fMFs c,m be produced by cells other 
than sqllamous carcinonHl. II .11.Is Recently, we could not 
demonstrate a direct correl:ltion between serum LMMF levels 
and defective monocyte polarization il/ vim.1.1 This argues 
against a direct effect of tumour-released LMMFs present in 
the circulation of a patient on the monocytes present in the 
same circulation. This notion is further sliPported by the pre-
sent finding thut the pl5E-like LMMF levels were not affected 
by the TPI injections, while there was a clear enect on the 
monocyle and dendritic cell functions. 
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In the present study we could not confirm earlier data on a 
predictive value orpl SE levels with regard to recurrence. This 
may be explained by the fact that in the earlier study only 
small numbers ofpatienlS were studied. 
In conclusion, the migrating function of monocyles and 
monocyte-derived dendritic cells is suppressed in patients with 
head and neck c;meer. Although it is likely thai factors 
released by the tumour are responsible for this suppression. 
this study did not show a simple (orrclation between the 
presence of riSE-like LMMFs in serum (most likely tumour-
derived) and a disturbed function of the patient's monocytes. 
Hence more factors are involved. TPI treatment did restore 
the suppressed function of Illonocytes. and monocyte-derived 
dendritic cells before surgical removal orthe tumour; however, 
TPI treatment aOer surgical removal did not contribute to a 
further improvement other than that produced by removal of 
the tumour. 
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GENERAL DISCUSSION 

General discussion B7 
Objectives 
Despite advances in surgical- and radiation techniques, as well as the 
introduction of various chemotherapeutic agents, survival of HNSCC patients 
has not improved over the past 3 decades. Intervention with the immune 
system using biologic response modifiers (BRM's), commonly called 
immunotherapy, has more recently become available, and has yielded 
reasonable succes rates in a number of cancers, especially in malignant 
melanoma and renal cell carcinoma (1,2]. Cytokine treatments (lL-2, IFN-ct) have 
been reported to achieve partial remissions in about 10-20% of patients with 
these tumors. Complete remissions are however rare and the partial remissions 
are not longlasting [3]. 
Significant clinical results from the use of BRM's have so far not been achieved 
in HNSCC patients. The in vivo studies, focussing on the immunomodulating 
drug thymostimulin (TP-1), described in this thesis show that: 
1. a recognizable pattern of lymphoid cell infiltration exists in head and 
neck squamous cell carcinoma's. Distinctive small stromal fields of T 
lymphocytes intermingled with dendritic cells can be seen, while tumors 
are generally densly infiltrated with macrophages. The T cell component 
of this infiltrate can significantly be enhanced by preoperative TP-1 
treatment. 
2. preoperative TP-1 treatment of head and neck squamous cell carcinoma 
patients results in 
a normalization of the disturbed monocyte polarisation 
a restoration of the disturbed dendritic cell clustering 
capability. 
3. removal of the tumor similarly results in a restoration of the disturbed 
dendritic cell clustering capability, and confirm earlier studies that after 
removal of the tumor a normalization of monocyte polarization occurs. 
4. neither TP-1 treatment nor removal of the tumor affects p15E-like low 
molecular mass factor levels in blood of head and neck squamous cell 
carcinoma patients, and that there is no spatial relationship of p15E-like 
factor positive cells in HNSCC and the infiltration with macrophages or 
dendritic cells. 
5. show that TP-1 treatment does not further enhance restoration of 
immune functions accomplished by surgery on a short or long-term 
basis. 
TP-1 has thus been shown in our studies to be a potent BRM. However TP-1 
is certainly not the only immunomodulating drug able to enhance immune 
functions in head and neck squamous cell carcinoma patients. A discussion of 
other potent BRM's follows below. 
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Other BRMs used in HNSCC 
The most widely studied agent in head and neck cancer is IL-2. IL-2 is a 15 kD 
glycoprotein, produced by activated CD4 + T lymphocytes, which is critical in 
the activation of cytotoxic cells that can mediate host anti-tumor activity. In 
HNSCC, IL-2 has been administered systemically as well as locally. The 
disadvantage of systemic administration is its dose-limiting severe toxicity [4]. 
Therefore, most studies have concentrated on local administration, which can 
be either intratumoral, peri-lymphatic, or intra-arterial through the external 
carotid artery and the main tumor arterial supply [5,6]. Although Matijssen [7] 
found no clinical responses and no immunohistochemical changes in the tumor-
infiltrate from perilymphatic IL-2 injections, most studies report differently. 
Denser infiltration of T lymphocytes [8,9], of CD1 a + dendritic cells [8], of NK-
cells [9], of LAK-cells [10], and of eosinophils [5], as well as an enhanced CD25 
(lL-2 receptor) expression [8-10] and TIL cytolytic activity [9] has been 
reported. However the few clinical responses are generally not long lasting [5]. 
Recent laboratory studies have shown some promising prospectives regarding 
IL-2 treatment. Firstly, a combination of IL-2 with IL-12, a cytokine that 
particularly stimulates the T helper-1 (TH1) response and also induces 
lymphocyte cytolytic activity, was in vitro found to activate cytolysis more than 
either cytokine alone [11]. Secondly, the use of mutant IL-2 molecules with 
various amino acid subtitutions resulted in less toxicity, and this might make 
systemic therapy more attractive [4]. Thirdly, in a study by Whiteside et al. 
[12], tumors arising from a HNSCC cell line transfected with the IL-2 gene, that 
were induced in immunosuppressed nude mice, regressed spontaneously. 
Translating this model to a clinical situation, it might mean that after removing 
cancer cells from a patient; the transduction of tumor cells ex vivo with 
cytokine genes, and a reintroduction of genetically engineered cells into the 
patient might lead to an immune response to the tumor. Since this approach 
is technically demanding, large scale clinical applications of this method may 
not be expected in the near future. 
Another group of cytokines that has been studied in the treatment of HNSCC, 
either alone or in combination with IL-2 are the interferons IFN-o: and IFN-y. By 
and large, IFN-o: augments MHC class I expression, while IFN-y upregulates 
class II antigens. Systemic IFN-o: treatment in combination with IL-2 [13,141, 
as well as IFN-o: alone [5,15] have been reported to have anti-tumor activity and 
to induce partial or complete responses in a low percentage of patients with 
head and neck cancer; however, improved survival rates due to these 
treatments have not been shown. IFN-y by itself has so far been found 
ineffective in the treatment of (head and neck) cancer [16,17]. 
Kimura [18] reported a significantly better 5 year cumulative survival rate in a 
group of head and neck cancer patients treated with Sizefilan (SPG) as adjuvent 
therapy, compared to a matched control group. SPG is a glucan produced by 
Schizophyllum commune Feries (a Basidiomycetes species), and is considered 
to stimulate the induction of a number of effector cells against tumors. 
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Unfortunately, the study mentioned above is on a small group of patients (15), 
and so far no larger studies have been reported confirming these findings. 
OK-432 is a preparation acquired from Streptococcus pyogenes A3. It 
stimulates the cytotoxic activity of macrophages, NK-cells, LAK-cells, and T 
cells; it also induces the production of a number of cytokines, including I L-1, IL-
2, IL-6, IFN, TNF, NKAF, and TGIF, a tumor growth inhibitory factor [19-21]. 
Patients preoperatively treated with local injections of ex vivo OK-432-cultured 
blood lymphocytes irt combination with radiotherapy or chemotherapy showed 
a dense infiltration of T lymphocytes in the tumor on immunohistochemical 
examination, and an overall response rate was observed in 88% of the patients 
[19]. A control group was however not mentioned in this study. In another 
study by Fukazawa [22], 78 patients received peri-operative OK-432 treatment 
(intramuscular injections) in combination with BCG, and Ge-132 (fl-carboxyethyl 
germanium sesquioxid, an interferon inducer). A significant better 5 year 
survival rate was observed compared to a historical control group (57.3% vs 
28.6%). Clearly, randomized, controled studies are needed to fully evaluate the 
use of OK-432 in the treatment of head and neck cancer. 
Although research concerning the use of BRM's in HNSCC treatment regimes 
has been going on for more than a decade, it has so far not yielded a 
widespread clinical application. It has become clear that it is certainly possible 
to boost the immune response, resulting in for instance an enhanced tumor 
infiltration by mononuclear cells and an enhanced cytotoxicity (see TP-1 and 
OK-432 treatments). This enhanced immune reactivity has however not yet 
been translated into a better survival of patients. Ongoing work on the use of 
ex vivo cultured and stimulated (tumor specific) cytotoxic cells, and on the use 
of gene-therapy may result in future more powerful immunomodulating 
treatments. In the meantime however we should also concentrate on disclosure 
of the tumor mechanisms of "immune resistance", viz the production of 
immunosuppressive agents by the cancer cells. This awareness of 
immunesuppressing capabilities of the HNSCC particularly applies to yet another 
new approach in immunotherapy, i.e. the vaccination with tumor-antigen loaded 
DC [23]. Recent research indicates that such vaccination indeed has a 
favourable outcome in both animal models of tumor growth as well as in cancer 
patients [24,25]. If - in addition to such vaccination - immunosuppressive TM-
factors influencing DC function could be neutralized with thymic factors or rt.-
TM antibodies even better outcomes might be expected. 
Conclusion 
Head and neck squamous cell carcinomas that become clinically evident are 
apparently resistant to the specific and non-specific arm of the cell mediated 
immune response. If this is a direct result of the well documented functional 
defects of CMI in HNSCC patients, which are, in part caused by factors 
produced by the tumors themselves, is not clear. Other deficits in the defence 
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mechanisms, like for instance the lack of expression of MHC-class II 
costimulatory molecules on tumor cells; the release of tumor (super-) antigens 
that anergize cytotoxic cells or an inadequate expression of MHC-class I 
molecules by the tumor cells may also playa role, while there may be many 
other unknown factors. 
Immunomodulating therapies have yielded some encouraging results (enhanced 
T cell infiltration, restoration of defective CM!), but have so far not resulted in 
an improved disease free survival in the majority of studies. Currently, ex vivo 
culture of tumor specific cytotoxic cells, the transduction of genes into tumor 
cells and the vaccination with tumor-peptide loaded DC seem to be the most 
promising strategies for the near-future. Research should further focus on the 
isolation of tumor infiltrated and TAA-specific lymphocytes, culturing these cells 
outside the body, and define optimal ways to activate and stimulate these cells 
with various cytokines like IL-2 and IL-12 before re-introducing them into the 
patient. Transduction of cytokine producing genes in such T cells which seems 
to work in animal models is already finding its application in humans, but the 
procedure using retroviral or adeno-associated vectors is complex. Furthermore, 
it must be kept in mind that small tumors may well be more susceptible to 
immuno-modulating therapy than large tumors, and that most trials have 
focussed on patients with advanced stage disease, while small tumors are often 
well managed by traditional techniques. In this respect (a combination of) 
agents may be more benificial in a perioperative adjuvant setting in case of 
smaller tumors. However, in view of the many different escape mechanisms 
cancers possess, it will be very difficult to find a generally acceptable, effective 
immuno-modulating therapy based on natural cytotoxicity. 
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SUMMARY 
In the general introduction (chapter 1), the basics of host defense are explained 
with special emphasis on tumor immunology, and on head and neck cancer in 
particular. The role of the various cells of the cell mediated immune system is 
discussed. Impairments of immune functions in head and neck squamous cell 
carcinoma patients are well documented, and a detailed discussion on such 
impairments is part of this chapter. Furthermore, immunosuppressive factors 
related to head and neck squamous cell carcinoma's are being eluded on. 
In chapter 2 the objectives of the studies described in this thesis are listed: 
1. The first objective was to give a detailed analysis of the pattern of head 
and neck cancer infiltration by macrophages, dendritic cells and T cells. 
2. The second objective was a study on the pattern of infiltration by 
macrophages and dendritic cells in relation to the immunohistomorpholo-
gical expression by the tumor cells of low molecular mass factors (so-called 
p15E-like or TM factors) that are capable of suppressing monocyte, 
macrophage and dendritic cell functions. 
3. The third objective was a study on the in vivo effects of a thymic hormone 
preparation (TP-1) on the 
disturbed monocyte polarization and dendritic cell clustering of HNSCC 
patients 
infiltration pattern of lymphocytes, macrophages and dendritic cells in 
HNSCC 
levels of the p15E-like factors in the peripheral blood of HNSCC patients. 
In chapter 3, a study is described which was designed to determine if a 
consistent infiltration pattern of lymphoid cells in previously untreated head and 
neck squamous cell carcinoma's could be detected. In the majority of tumors 
a recognizable pattern was seen. The stroma of the tumors contained distinctive 
small fields of T lymphocytes, intermingled with Sl 00 + /RFD1 + /L25 + dendritic 
cells. Intra-epithelial T cell and dendritic cell infiltration was low, the intra-
epithelial dendritic cell infiltration mainly being S 100 + dendritic cells. CD68 + 
macrophage infiltration was markedly present in both stroma and tumor nests, 
although the latter being less dense than the stromal infiltration. In nearly half 
of the specimens studied granulomatous structures of densly packed 
macrophages, intrastromally located at the borders of tumor nests were seen. 
The histochemical localizati.on of the tumor infiltrating dendritic cells and 
macro phages supports the view that the former cells are involved in the 
sensitization to tumor antigens, whereas the latter cells are involved in tumor 
cytotoxicity/scavenging of tumor cell debris. In all tumors, the malignant 
epithelial cells stained positive to at least some degree for the anti-p15E 
antibody 4F5. The expression varied from weak to strong between tumors and 
was associated with the histological grade of the tumors. There was no 
relationship between the intensity of p15E expression and the severity of 
lymphoid cell infiltration of any kind. 
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Chapter 4 describes the in vivo effects of 10 days of preoperative 
thymostimulin (TP-1) treatment of head and neck squamous cell carcinoma 
patients on a) the polarization capability of peripheral blood monocytes as a 
measure of chemotaxis, b) the capability of peripheral blood dendritic cells to 
form cell clusters, and c) the level of p15E-like trans-membrane factors in blood. 
This study firstly confirmed earlier findings that a significant number of head 
and neck squamous cell carcinoma patients have a depressed monocyte 
polarisation assay, a defective capability of dendritic cells to form cell clusters 
with T-cells, and elevated levels of immunosuppressive p15E-like low molecular 
mass factors (LMMF's). Patients were treated in a double blind fashion with 
intramuscular injections of either TP-1 in one of three dosages (0.5 mg/kg, 1.0 
mg/kg, 2.0 mg/kg body weight) or a placebo. Assessment of monocyte 
polarization, the capability of dendritic cells to form clusters, and the presence 
of p15E-like LMMF's in serum was performed before TP-1 treatment and on the 
day of surgery. Findings demonstrated that TP-1 in a dose of 1.0 mg/kg and 2.0 
mg/kg bodyweight resulted in a normalization of the impaired monocyte 
polarization. Although the cluster capability of dendritic cells improved after TP-
1 treatment, values only reached statistical significance for the 0.5 mg/kg 
treatment group. Serum p15E-like LMMF levels were not affected by TP-1 
treatment in any of the patient groups. No correlation was found between 
elevated immunosuppressive LMMF's and defective monocyte polarization or 
cluster capability of dendritic cells. 
Chapter 5 describes the infiltration pattern of lymphoid cells into head and neck 
squamous cell carcinoma's of patients preoperatively treated with the 
immunomodulating drug thymostimulin (TP-1) as compared to non TP-1-treated 
patients. For all dosages of TP-1 used (0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kgl, a 
highly significant denser T cell infiltration into the stromal tissue of the tumors 
was observed compared to tumors of patients not treated with TP-1. 
Intraepithelial infiltration of T cells appeared to be denser in TP-1 treated 
patients, this was however not statistically significant. The quantitive infiltration 
of macrophages and dendritic cells was not affected by TP-1. Correlations 
between the presence of the various tumor infiltrating cells, and the outcome 
of the monocyte polarization assay as an indicator of monocyte chemotaxis, 
and dendritic cell cluster capabilily of peripheral blood monocytes/dendritic cells, 
as well as numbers of peripheral blood T cells, were also studied. A positive 
correlation was found for tumor T cell infiltration and the capability of peripheral 
blood dendritic cells to form cell clusters with T cells. No correlation existed 
between T cell numbers in peripheral blood and T cell infiltration into the tumor; 
nor was the monocyte polarization of peripheral blood monocytes correlated 
with tumor infiltration of monocytes or monocyte-derived macrophages or 
dendritic cells. 
In chapter 6 the long-term effects of thymostimulin (TP-1) treatment of head 
and neck squamous cell carcinoma patients on monocyte polarization and 
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dendritic cell clustering of peripheral blood monocytes/dendritic cells are 
described. These immune parameters were studied in 39 patients treated with 
TP-1 in one of three dosages (0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg body weight) 
for 10 days pre- and 6 months postoperatively, and in 22 patients who were 
not treated with TP-1. 
In the non-TP-1 treated group we confirmed that surgical removal of the tumor 
resulted in a restoration of monocyte and dendritic cell functions (as was 
preoperatively seen for patients treated with TP-1, see chapter 3); TP-1 
treatment gave no additional effect to this restoration. At the end of the 
treatment period (day 180), a difference of monocyte polarization between TP-1 
treated patients and non-TP-1 treated patients could be demonstrated, 
suggesting a renewed disturbance of monocyte polarization in the non-TP-1 
treated patients; however, for the dendritic cell cluster assay no differences 
between the 2 groups were found at that time. P15E-like LMMF levels in the 
blood of both TP-1 treated and non-TP-1 treated patients remained elevated, 
even after removal of the tumor. It is therefore unlikely that depression of 
cellular immunity is a direct effect of these LMMF's. A comment on the clinical 
effects (survival) of TP-1 is made in this chapter: beneficial effects were not 
recorded in this dose-finding study. 
The general discussion (chapter 7) firstly lists again the outcomes of our studies 
and further focusses on biologic response modifiers (BRM's) in use in respect 
to head and neck cancer. These BRM's concern Thymostimulin, IL-2, interferons 
IFN-a and IFN-y, Sizofilan, and OK-432. Although encouraging laboratory results 
were achieved for most of these BRM's, clinical effects have generally been 
disappointing. Future strategies are discussed in this chapter. We conclude that 
it will be very difficult to find a generally acceptable, effective immuno-
modulating therapy based on natural cytotoxicity, due to the many escape 
mechanisms the cancers possess. 

5AMENVATTING 
In de introductie (hoofdstuk 1), wordt de basis van het afweermechanisme 
uitgelegd met speciale nadruk op tumorimmunologie en die van hoofd/hals-
kanker in het bijzonder. De rol van de verschillende cellen van de cellulaire 
immuniteit wordt besproken. Verstoringen van de immuunfunctie van patienten 
met een hoofd/halscarcinoom zijn goed gedocumenteerd en een gedetailleerde 
discussie is deel van dit hoofdstuk. Daarbij worden met name 
immunosuppressieve factoren behandeld in relatie tot dit carcinoom. 
In hoofdstuk 2 worden de doelstellingen van dit proefschrift beschreven: 
1. De eerste doelstelling was een gedetailleerde beschrijving te geven van het 
infiltratiepatroon van hoofd/halscarcinomen door macrofagen, dendritische 
cellen en T-cellen. 
2. De tweede doelstelling betrof het infiltratiepatroon van deze cell en in relatie 
tot de immunohistochemische expressie van laag moleculaire gewichts-
factoren (zgn. p15E-achtige of transmembranale (TM) factoren) door 
tumorcellen. Deze factoren zijn in staat om monocyt-, macrofaag- en 
dendritische celfuncties te verstoren. 
3. De derde doelstelling was het bestuderen van de in vivo effecten van een 
thymushormoonpreparaat (TP-1) op 
de verstoorde monocytenpolarisatie en dendritische celclustering bij 
hoofd/halscarcinoompatiiinten. 
het infiltratiepatroon van Iymfocyten, macrofagen en dendritische cellen 
van hoofd/halscarcinomen. 
de concentratie van de p15E-achtige factoren in het perifere bloed van 
hoofd/halscarcinoompatienten. 
In hoofdstuk 3 wordt een basale studie beschreven die ontworpen is om te 
bepalen of een constant patroon van celinfiltratie van Iymfo'ide cellen in 
voorheen onbehandelde hoofd/halscarcinomen vastgesteld kon worden. In het 
merendeel van de tumoren werd een duidelijk herkenbaar patroon gezien. Het 
stroma van deze tumoren bevatte omschreven kleine veldjes van T-Iymfocyten, 
waartussen zich 5100+ IRFD1 +/L25 + dendritische cellen bevonden. Intra-
epitheliale T-cel en dendritische celinfiltratie was gering; de intra-epitheliale 
dendritische celinfiltratie bestond voornamelijk uit 8100+ dendritische cellen. 
CD68 + macrofageninfiltratie was uitgesproken aanwezig in het stroma en de 
tumornesten. In het epitheel was de infiltratie duidelijk minder dicht dan in het 
stroma. In bJ/na de helft van de tumoren werden granulomateuze structuren van 
zeer dJcht opeengepakte macrofagen gezien die zich in het stroma dicht tegen 
de tumornesten aan bevonden. Deze immunohistochemische localisatie van 
tumor infiltrerende dendritische cellen en macrofagen steunen de opvatting dat 
de eerstgenoemde cellen betrokken zijn bij de sensibilisatie tegen 
tumorantigenen, terwijl de laatstgenoemde cellen betrokken zijn bij 
tumorcytotoxiteit en opruimen van tumorceldebris. In aile tumoren kleurde het 
maligne plaveiselcelepitheel aan voor het anti-p15E antilichaam 4F5. P15E is 
een eiwit dat geassocieerd wordt met immunosuppressieve eigenschappen van 
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hoofd/halstumoren. De expressie hiervan varieerde van zwak tot sterk en was 
geassocieerd met de differentiatiegraad van de tumoren. Er was geen relatie 
tussen de intensiteit van p 15E expressie en de graad van Iymfo'lde celinfiltratie. 
Hoofdstuk 4 beschrijft de in vivo effecten van 10 dagen pre-operatieve 
behandeling met thymostimuline (TP-1) van patienten met een plaveiselcel-
carcinoom in het hoofd/halsgebied op a) de monocytenpolarisatie van perifere 
bloedmonocyten als een maat voor chemotaxis, b) de clustervormende 
eigenschappen van dendritische cellen in het perifere bloed en c) de hoeveelheid 
van p15E-achtige TM factoren in het bloed. Deze studie bevestigde eerdere 
bevindingen dat een significant aantal van hoofd/halscarcinoompatienten een 
gestoorde monocytenpolarisatie heeft, een verminderde clustervorming van 
dendritische cellen met T-cellen en een verhoogde hoeveelheid van 
immunosuppressieve p15E-achtige laag moleculaire gewicht factoren (LMMF's) 
in het bloed. Patienten werden behandeld met intramusculaire injecties van 
of wei TP-1, in een van drie doseringen (0,5 mg/kg, 1.0 mg/kg of 2.0 mg/kg 
lichaamsgewicht) of een placebo. De monocytenpolarisatie, de dendritische 
celclustervorming en de aanwezigheid van p15E-achtige LMMF's in het serum 
werden bepaald v66r TP-1 behandeling en op de dag van chirurgie (meestal dag 
10). TP-1 in een dosering van 1.0 mg/kg en 2.0 mg/kg lichaamsgewicht 
resulteerde in een normalisatie van de verstoorde monocytenpolarisatie. De 
dendritische celclustervorming verbeterde ook na TP-1 behandeling; dit bleek 
echter aileen significant voor de 0.5 mg/kg groep. Serum p15E-achtige LMMF's 
werd niet be'lnvloed door TP-1 behandeling (in geen van de doseringen). Er werd 
geen correlatie gezien tussen een verhoogde hoeveelheid immunosuppressieve 
LMMF's in het bloed en een verstoorde monocytenpolarisatie of dendritische 
celclustering. 
Hoofdstuk 5 beschrijft het patroon van infiltratie van Iymfo'lde cellen in 
hoofd/halscarcinomen van patienten die pre-operatief behandeld zijn met 
thymostimuline (TP-1), vergeleken met tumoren van niet met TP-1 behandelde 
patienten. Voor aile doseringen TP-1 die gebruikt zijn (0.5 mg/kg, 1.0 mg/kg, 
2.0 mg/kg lichaamsgewicht), werd een haag significant dichtere T- celinfiltratie 
van het tumorstroma gezien verge Ie ken met tumoren van patienten die niet met 
TP-1 behandeld waren. Ook intra-epitheliale infiltratie van T-cellen leek dichter 
te zijn in tumoren van met TP-1 behandelde patienten; dit bleek echter een niet 
statistisch significant verschil te zijn. De kwantitatieve infiltratie van macrofagen 
en dendritische cellen werd niet door TP-1 be'lnvloed. Voorts werden correlaties 
bestudeerd tussen de aanwezigheid van verschillende tumarinfiltrerende cellen 
en 1) het resultaat van de monocytenpolarisatie (als een indicator van de 
monocytenchemotaxis), 2) de dendritische celclustering en 3) aantallen van 
perifere T-cellen. Een positieve correlatie werd gevonden voor de T-celinfiltratie 
van tumoren en de mogelijkheid van dendritische cellen uit het perifere bloed om 
celclusters met T-cellen te vormen. Er was geen correlatie tussen T-cel aantallen 
in het perifere bloed en T-celinfiltratie in de tumor, noch was de 
Samenvatting 99 
monocytenpolarisatie van perifere monocyten gecorreleerd met infiltratie in de 
tumor door macrofagen of dendritische cellen. 
Hoofdstuk 6 gaat over de effecten op lange termijn van thymostimuline (TP-l)-
behandeling van patienten met een hoofd/halscarcinoom op de monocyten-
polarisatie en dendritische celclustering. Deze immunoparameters werden 
bestudeerd bij 39 patienten die TP-l kregen in 1 van de 3 doseringen (0,5 
mg/kg, 1,0 mg/kg, 2,0 mg/kg lichaamsgewicht) gedurende 10 dagen pre-
operatief en 6 maanden postoperatief. Deze parameters werden tevens 
bestudeerd bij 22 patienten die niet met TP-l behandeld werden. In de groep 
patienten die niet met TP-l behandeld werden resulteerde het chirurgisch 
verwijderen van tumor in een herstel van de monocytenpolarisatie en de 
dendritische celclustering (zoals pre-operatief reeds werd gezien bij patienten die 
met TP-l behandeld werden, zie hoofdstuk 3); TP-l behandeling gaf geen 
additioneel effect. Aan het eind van de behandelingsperiode (dag 180), werd 
een verschil tussen de monocytenpolarisatie van TP-l behandelde patienten en 
niet met TP-l behandelde patienten gezien, hetgeen suggereert dat de 
monocytenpolarisatie bij niet met TP-l behandelde patienten opnieuw verstoord 
zou zijn. Voor de dendritische celclustering konden op dat moment geen 
verschillen aangetoond worden. P15E-achtige LMMF concentraties in het bloed 
van met TP-l behandelde en niet met TP-l behandelde patienten, bleven 
verhoogd, zelfs na verwijdering van de tumor. Het is daarom onwaarschijnlijk 
dat de depressie van de cellulaire immuniteit een direct effect is van deze 
LMMF's. De mogelijke klinische effecten van TP-l worden van commentaar 
voorzien in dit hoofdstuk; positieve klinische effecten werden niet vastgesteld 
in deze dose-finding studie. 
De discussie (hoofdstuk 7) vat onze studieresultaten samen en spitst zich verder 
toe op "biologic response modifiers" (BRM's) die (in experimentele opstelling) 
gebruikt worden bij de behandeling van hoofd/halscarcinomen. Deze BRM's 
betreffen Thymostimuline, IL-2, de interferonen IFN-alpha en IFN-gamma, 
Sizofilan en OK-432. Alhoewel de cellulaire immuniteit in gunstige zin wordt 
be'invloed door de meeste van deze BRM's, blijven de klinische effecten daarbij 
teleurstellend achter. Mogelijke toekomstige onderzoeks- en behandelings-
strategieen op gebied van tumorimmunologie van het hoofd/halsgebied worden 
in dit hoofdstuk besproken. Geconcludeerd wordt echter dat het zeer moeilijk 
zal zijn een acceptabele, op natuurlijke cytotoxiteit gebaseerde, effectieve 
immunomodulerende therapie te vinden vanwege de vele ontsnappings-
mechanismen die deze carcinomen bezitten. 
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